Fusion proteins containing Circoviridae capsid proteins and chimeric virus-like particles composed thereof

Abstract

The present invention relates to recombinantly constructed polypeptides useful for preparing vaccines, particularly for reducing one or more clinical signs caused by infection with at least one pathogen, e.g., viral infection. More specifically, the present invention relates to polypeptides comprising a Circoviridae capsid protein linked to a heterologous protein or a fragment thereof, and chimeric virus-like particles comprised of such polypeptides. In one example, a fusion protein is provided that comprises a PCV2 ORF2 protein linked to an immunogenic fragment of a rotavirus VP8 protein and is useful for reducing one or more clinical signs, mortality, or fecal shedding caused by rotavirus infection in animals of the genus Sus.

Description

[Technical Field]

[0001] The present invention relates to recombinantly constructed polypeptides useful for preparing vaccines, particularly for reducing one or more clinical signs caused by infection with at least one pathogen, e.g., viral infection. More specifically, the present invention is directed to polypeptides comprising a Circoviridae capsid protein linked to a heterologous protein or a fragment thereof, and chimeric virus-like particles composed of such polypeptides. In one example, a fusion protein is provided that comprises a PCV2 ORF2 protein linked to an immunogenic fragment of a rotavirus VP8 protein, and is useful for reducing one or more clinical signs, mortality, or fecal shedding caused by rotavirus infection in animals of the genus Sus. [Background technology]

[0002] Background information A family of viruses named Circoviridae, found in a range of plant and animal species and commonly referred to as circoviruses, are characterized as circular, non-enveloped virions with icosahedral capsids composed of 60 copies of a single protein. The ssDNA genome of circoviruses represents the smallest known viral DNA replicon.

[0003] Animal viruses included in this family are chicken anemia virus (CAV), pigeon circovirus, beak and feather disease virus (BFDV), bat-associated circovirus and porcine circovirus (PCV).One of the most economically serious circoviruses is porcine circovirus type 2 (PCV2), which is the cause of porcine circovirus-associated disease. The PCV2 ORF gene can be expressed in insect cell culture. It has also been shown that the PCV2 ORF2 protein assembles into virus-like particles (VLPs). These VLPs are essentially empty PCV2 capsids and are highly immunogenic. Several attempts to utilize the PCV2 ORF2 protein as an antigen carrier have been described in the literature: sequences encoding short (≤30 amino acids) peptides have been added to the 3' end of the PCV2 ORF2 reading frame and inserted into the region encoding the surface-exposed loop.

[0004] Both VLPs expressed using recombinant PCV2 virus and baculovirus-infected insect cells display peptides on the particle surface (Beach et al. J Virol. 85(9): 4591-4595 (2011); Huang et al. Virus Res. 161: 115-123 (2011); Li et al. Vet Microbiol. 163: 23-32 (2013); Huang et al. Appl Microbiol Biotechnol. 98: 9339-9350 (2014); Hu et al. Vaccine 34: 1896-1903 (2016); Wang et al. Front Cell Infect Micriobiol. 8: 232 (2018); Ding et al. Adv Healthcare Mater. 1900456 (2019); Wang et al. Vet. Microbiol. 235: 86-92 (2019)). These further include WO 2009088950A2 along with the more recent WO 2016160761A2. To date, the literature has not described the expression of a single polypeptide consisting of a circovirus capsid protein and a second protein or protein domain of significant length, resulting in the second protein or protein domain being displayed on the outer surface of the circovirus capsid or VLP. Recently, PCV2 ORF2 expressed with a 7-amino acid Q-tag sequence inserted into either the BC loop or the C-terminal extension was conjugated to enhanced green fluorescent protein (EGFP) expressed with a 6-amino acid K-tag C-terminal extension. This conjugation requires separate expression and purification of the modified PCV2 ORF2, EGFP, and a microbial transglutaminase to catalyze the reaction between the Q-tag and K-tag. Furthermore, conjugation confirmed the absence of VLPs (Masuda et al. J Insect Biotechnol Sericol. 87: 53-60 (2018)).

[0005] However, to induce a sufficient immune response to achieve adequate vaccination, it may be necessary to conjugate antigens, particularly protein domains or proteins, longer than 30 amino acid residues to a carrier protein. In this regard, it is desirable that such fusion proteins can be expressed by cells as a single molecule that can homomultimerize to form virus-like particles (VLPs), which then induces proper folding and presentation of the longer antigen on the surface of the particle so that the antigen is sufficiently immunogenic to induce the required immune response. Thus, there is a need for polypeptides comprising carrier proteins conjugated to longer antigens, where the fusion proteins have the advantageous properties described above. It would also be desirable to generate such fusion proteins that are capable of inducing an appropriate immune response against viruses with complex virions, such as rotavirus.

[0006] Rotavirus is a double-stranded RNA virus that comprises a genus within the Reoviridae family. Rotavirus infection is known to cause gastrointestinal illness and is considered the most common cause of gastroenteritis in young children. Rotavirus is transmitted by the fecal-oral route and infects cells lining the small intestine. Infected cells produce enterotoxins that induce gastroenteritis, resulting in severe diarrhea and sometimes death from dehydration. Rotaviruses have a genome composed of 11 segments of double-stranded RNA (dsRNA) and are currently classified into eight groups (A-H) based on antigenicity and a classification based on the sequence of the internal viral capsid protein 6 (VP6), as defined by the International Committee on Taxonomy of Viruses (ICTV) and summarized by Matthijnssens et al. (Arch Virol 157:1177-1182 (2012)) (this publication and further publications mentioned herein are incorporated by reference in their entirety). The rotavirus genome encodes six structural proteins (VP1 to VP4, VP6, and VP7) and six nonstructural proteins (NSP1 to NSP6), where genome segments 1 to 10 each encode one rotavirus protein and genome segment 11 encodes two proteins (NSP5 and NSP6).

[0007] In the context of rotavirus A, various strains can be classified as genotypes (defined by comparative sequence analysis and / or nucleic acid hybridization data) or serotypes (defined by serological assays) based on the structural proteins VP7 and VP4. VP7 and VP4 are components of the outermost protein layer (outer capsid), and both contain neutralizing epitopes. VP7 is a glycoprotein that forms the outer layer or surface of the virion (hence the designation "G"). VP7 determines the G type of strain, and the assigned numbers for G serotypes and G genotypes are identical. VP4 is sensitive to proteases (hence the designation "P") and determines the P type of the virus. In contrast to G types, the assigned numbers for P serotypes and genotypes are different (Santos N. et Hoshino Y., 2005, Reviews in Medical Virology, 15, 29-56). Thus, P serotypes are represented as P followed by an assigned number, and P genotypes are represented by P followed by an assigned number in parentheses (e.g., "P[7]" or "P

[13] "). Strains belonging to the same genotype have greater than 89% amino acid sequence identity (Estes and Kapikian. Rotaviruses. In: Knipe, DM; Howley, PM Fields Virology, 5th ed.; Wolters Kluwer / Lippincott Williams & Wilkins Health: Philadelphia, PA, USA (2007); Gorziglia et al. Proc Natl Acad Sci US A. 87(18):7155-9 (1990)).

[0008] Rotaviruses are also a major cause of gastroenteritis in animals, particularly Sus scrofa, with antibodies to group A and C rotaviruses present in nearly 100% of pigs (Vlasova et al. Viruses. 9(3): 48 (2017)). Currently, only modified live or killed vaccines are available against rotavirus A. The inability to cultivate rotavirus C in the laboratory hinders the development of vaccines against this group, which in turn makes recombinant vaccines more attractive.

[0009] The creation of recombinant antirotavirus vaccines is hindered by the complexity of the rotavirus capsid, which is composed of four proteins arranged in three layers. The innermost layer is composed of 60 dimers of VP2 with T=1 symmetry. The VP2 layer is necessary for the proper ordering of the middle layer, formed by 260 trimers of VP6 with T=13 symmetry. The resulting symmetry mismatch between VP2 and VP6 results in five distinct VP6 trimer positions and three distinct pore types. In the absence of VP2, VP6 readily forms ordered, high-molecular-weight microtubules and globules in a salt- and pH-dependent manner, which may represent a by-product of virus assembly. In the capsid, the VP6 layer binds 260 Ca of VP7, which acts as a clamp to hold the VP4 spike in place. 2+ The VP7 is glycosylated or a G-type antigen and contains neutralizing epitopes. Most neutralizing antibodies recognize only trimeric VP7 and are thought to act by preventing dissociation of the VP7 trimer, thereby blocking spike release. Rotavirus spikes exist as 60 trimers of VP4 that are inserted into the VP6 layer only in type II pores. VP4 contains neutralizing epitopes and is a P-type antigen, and is synthesized by trypsin into the spike base VP5. * , and after cleavage, VP5 * Cell-interacting head VP8 remains associated with *Trypsin treatment primes the spikes for cell entry, during which they undergo extensive structural rearrangements to expose active sites for receptor binding in host cells. Despite the complexity of the assembly process, achieving stoichiometric expression of rotavirus capsid proteins in environmental conditions that promote proper assembly is challenging.

[0010] Given the difficulties of rotavirus capsid assembly, there has been interest in subunit vaccine approaches. VP7 and VP4 are two proteins that contain neutralizing epitopes; however, the utilization of VP7 would be complicated by its glycosylation and calcium-dependent trimerization. The utilization of VP4 would be complicated by its trimerization, trypsinization, and range of potential conformational states. The VP8 domain, or VP8, generated by trypsinization of VP4. * The VP8 protein, also named VP8, contains neutralizing epitopes, is monomeric, its structure has been determined at high resolution (Dormitzer et al. EMBO J. 21(5): 885-897 (2002)), and is described as very stable. Furthermore, within the VP8 protein, a lectin-like domain (aa 65-224) is thought to interact with host receptors and be involved in the attachment of the virus to host cells (Rodriguez et al., PloS Pathog. 10(5):e1004157 (2014)).

[0011] An approach to develop a rotavirus subunit vaccine for children is described, in which a tetanus toxoid universal CD4 + A truncated VP8 protein (VP8) linked to the T cell epitope (aa 830-844) P2 *A variant of VP8 (amino acid residues 64 (or 65) to 223) of VP8 (V64) was produced in Escherichia coli (Wen et al. Vaccine. 32(35): 4420-7 (2014)) and tested in infants (Groome et al. Lancet Infect Dis. 17(8): 843-853 (2017)). However, this use of a monovalent subunit vaccine (based on the truncated VP8 protein of rotavirus genotype P[8]) elicited inadequate responses against heterotypic rotavirus strains, and a trivalent vaccine formulation (genotypes P[4], P[6], and P[8]) was recently tested (Groome et al. Lancet Infect Dis. S1473-3099(20)30001 (2020)).

[0012] In another approach, the N-terminally truncated VP8 protein "VP8-1" (aa 26-241) was fused at the N- or C-terminus to the pentameric, non-toxic B subunit of cholera toxin (CTB). Of the resulting pentameric fusion proteins (CTB-VP8-1, VP8-1-CTB), only CTB-VP8-1 (i.e., VP8-1 fused N-terminally to CTB) was considered a viable candidate for further development compared with VP8-1-CTB, as it demonstrated a significant inhibitory effect of GM1 or VP8 in mouse models. * It showed higher avidity for conformations sensitive to specific neutralizing monoclonal antibodies, elicited higher titers of neutralizing antibodies, and conferred greater protective efficacy (Xue et al. Hum Vaccin Immunother. 12(11) 2959-2968 (2016)). However, given the difficulties of rotavirus capsid assembly, there is interest in alternative subunit vaccine approaches, especially since subunit vaccines are generally considered very safe. Furthermore, recombinant expression of effective rotavirus subunit antigens, which would allow for the simple generation of vaccine antigens for such rotaviruses, which are difficult to cultivate, is highly desirable. Furthermore, because rotaviruses are a major cause of gastroenteritis in wild boars, there is a strong need for subunit vaccines for wild boars, particularly those containing antigens that allow for efficacy comparable to or even better than that of the MLV rotavirus vaccines currently commercially available for wild boars. Summary of the Invention

[0013] Description of the Invention The solution to the above technical problem is achieved by the description and embodiments characterized in the claims. Therefore, the invention in its different aspects is carried out according to the claims. The present invention is based on the surprising discovery that when Circoviridae viral capsid proteins are conjugated to non-Circoviridae antigens that are substantially longer than the known 30 amino acid residue length, this creates stable chimeric virus-like particles that display the non-Circoviridae antigen on their surface. [Brief explanation of the drawings]

[0014] [Figure 1] FIG. 1 shows negative staining electron microscope images of PCV2 ORF2 protein VLPs. [Figure 2] FIG. 1 shows negative staining electron microscope images of PCV2-CVP8 protein VLPs. [Figure 3]FIG. 1 shows serum IgG responses of pigs vaccinated with either PCV2-AVP8 protein formulated with Emulsigen D (results represented in the line graph by the (upper) line starting on study day -1) or placebo (results represented in the line graph by the (lower) line starting on study day 1). [Figure 4] FIG. 1 shows the results of a VN (virus neutralization) assay performed to detect and quantify antibodies capable of neutralizing porcine rotavirus A virus in samples from pigs vaccinated with PCV2-AVP8 protein formulated with Emulsigen D (labeled "PCV2 ORF2 VLP carrier AVP8") or placebo ("irrelevant vaccine control"). [Figure 5] Figure 1 shows mean VN titers against rotavirus in sow sera by group and study day, where study days D0 and D28 represent the "6 weeks and 2 weeks before farrowing" time points (i.e., when the investigational product was administered to the TOl and TO2 study groups, respectively), and study days D7, D28, and D35 represent the "5 weeks, 2 weeks, and 1 week before farrowing" time points (i.e., when the commercial vaccine was administered to TO6). [Figure 6] FIG. 1 shows group median log rotavirus A RNA genome copies (gc) / mL in stool by study day. [Figure 7] FIG. 1 shows group median anti-PCV2 titers (bar = range) in serum by study day. DETAILED DESCRIPTION OF THE INVENTION

[0015] In particular, we unexpectedly found that fusing a large fragment of the rotavirus A or C VP8 protein to the C-terminus of the PCV2 ORF2 protein allows the formation of rotavirus-associated VLPs without the difficulty of assembling into a three-layered rotavirus capsid. These fusion protein partners are significantly larger than the ≤30 amino acid fusions previously described in the literature, measuring 168 amino acid residues (a fragment of the rotavirus A VP8 protein) and 181 amino acid residues (a fragment of the rotavirus C VP8 protein), which approximates the size of the 233 or 234 amino acid residues of PCV2 ORF2. Administration of such polypeptides containing an immunogenic fragment of the rotavirus VP8 protein linked to the PCV2 ORF2 protein to sows significantly reduced clinical signs and fecal shedding, as well as mortality, in their offspring after rotavirus challenge via passive transfer of neutralizing antibodies.

[0016] In a first aspect, the present invention therefore relates to a polypeptide comprising a Circoviridae virus capsid protein linked to a heterologous protein or a fragment thereof, said polypeptide being hereinafter also referred to as "polypeptide of the invention". In a particularly preferred embodiment, the polypeptide of the present invention consists of a Circoviridae virus capsid protein linked to a heterologous protein or fragment thereof, where, optionally, said capsid protein is linked to the heterologous protein or fragment thereof via a linker moiety.

[0017] As used herein, the term "polypeptide" specifically refers to any chain of amino acid residues linked together by peptide bonds, and does not refer to a specific length of the product. For example, "polypeptide" can refer to a long chain of amino acid residues, e.g., 150 to 600 amino acid residues in length, or longer. The term "polypeptide" includes polypeptides having one or more post-translational modifications, including, for example, glycosylation, phosphorylation, lipidation (e.g., myristoylation), acetylation, ubiquitination, sulfation, ADP-ribosylation, hydroxylation, Cys / Met oxidation, carboxylation, methylation, and the like. The terms "polypeptide" and "protein" are used interchangeably in the context of the present invention.

[0018] The term "Circoviridae virus capsid protein", as used herein, is understood to be equivalent to, among other things, "capsid protein of a Circoviridae virus". "Capsid protein", as used herein, refers in particular to a protein that can be incorporated into or naturally found in the capsid, i.e., the protein shell of a virus or virus-like particle, respectively. The term "Circoviridae virus capsid protein" in the context of the present invention is understood to be in particular a protein that has an amino acid sequence derived from the genome of a Circoviridae virus and that is capable of forming a virus-like particle by self-assembly with further subunits of the same protein. Preferably, the Circoviridae virus capsid protein is a full-length capsid protein of a Circoviridae virus, for example, a full-length PCV2 ORF2 protein.

[0019] A "heterologous protein" in the context of the present invention particularly relates to a protein derived from an entity other than the Circoviridae virus from which the capsid protein referred to herein is derived. Thus, in one example, when the Circoviridae virus capsid protein is the Porcine Circovirus Type 2 (PCV2) ORF2 protein, said heterologous protein or a fragment thereof comprises or consists of an amino acid sequence not found in PCV2. Preferably, the heterologous protein or a fragment thereof is a protein or a fragment thereof encoded by the genome of a virus other than a Circoviridae virus, for example, by the genome of a rotavirus.

[0020] Thus, the heterologous proteins referred to herein are, in particular, non-Circoviridae proteins, and the "fragments thereof" are, in particular, fragments of non-Circoviridae proteins. A "non-Circoviridae protein," as referred to herein, particularly relates to a protein not found in a Circoviridae virus. It is further understood that a "fragment of a non-Circoviridae protein" has, in particular, an amino acid sequence not found in a Circoviridae virus. More specifically, the heterologous proteins referred to herein are proteins encoded by the genome of a pathogen other than a Ciroviridae virus, and the "fragments thereof" are, in particular, fragments of a protein encoded by the genome of a pathogen other than a Ciroviridae virus. As a non-limiting example, the heterologous protein referred to herein may be a rotavirus VP8 protein.

[0021] As used herein, the term "fragment thereof" refers to a fragment of a heterologous protein that has the same activity, or type of activity, respectively, with respect to a specific functionality identified for the full-length heterologous protein. More specifically, the term "fragment thereof" relates to a fragment of a heterologous protein that comprises or consists of a protein domain, in particular a protein domain of the heterologous protein. Thus, a heterologous protein or a fragment thereof preferably comprises or consists of a protein domain. The protein domain is preferably at least 50 amino acid residues in length, more preferably at least 100 amino acid residues in length, and most preferably at least 150 amino acid residues in length. The term "protein domain," as used herein, refers to a region of a protein that has a particular three-dimensional structure with functional characteristics independent of the rest of the protein. This structure can provide the protein with a particular activity. Exemplary activities include, but are not limited to, enzymatic activity, creating a recognition motif for another molecule, or providing a necessary structural component for the protein in a particular environment. Protein domains are typically evolutionarily conserved regions of proteins both within protein families and within protein superfamilies that perform similar functions. A non-limiting example of a protein domain is the lectin-like domain of the rotavirus A VP8 protein. Thus, in a non-limiting example, the fragment of the heterologous protein, as referred to herein, may be a fragment of a rotavirus A VP8 protein, wherein the fragment is at least 150 amino acid residues in length, e.g., 150 to 200 amino acid residues in length, and / or the fragment comprises the lectin-like domain of a rotavirus A VP8 protein.

[0022] The term "linked to" as used herein refers to any means for connecting a Circoviridae virus capsid protein to a heterologous protein or fragment thereof, particularly within a polypeptide. Examples of the meaning of linked include (1) indirect linkage of a Circoviridae virus capsid protein to a heterologous protein or fragment thereof by an intervening moiety that is directly linked to the heterologous protein or fragment thereof and also binds to said Circoviridae virus capsid protein, and (2) direct linkage of a Circoviridae virus capsid protein to a heterologous protein or fragment thereof by a covalent bond. The terms "linked to" and "linked with" are used interchangeably in the context of the present invention.

[0023] In particular, the expression "a polypeptide comprising a Circoviridae virus capsid protein linked to a heterologous protein or a fragment thereof" as used herein means: " - Amino acid sequences of capsid proteins of Circoviridae viruses, and - the amino acid sequence of the heterologous protein or a fragment thereof, "a polypeptide comprising It is understood that this is equivalent to the expression: The term "heterologous protein or fragment thereof", when used herein, is particularly understood to be equivalent to "heterologous protein or a fragment of said heterologous protein". The expression "Circoviridae virus capsid protein linked to a heterologous protein or a fragment thereof", when used herein, is particularly understood to be equivalent to "Circoviridae virus capsid protein linked to a heterologous protein or a fragment of said heterologous protein". In a preferred embodiment, the C-terminal amino acid residue of the Circoviridae virus capsid protein is linked to the N-terminal amino acid residue of the heterologous protein or fragment thereof.

[0024] Preferably, the capsid protein is linked to the heterologous protein or fragment thereof via a linker moiety. A linker moiety, as described herein, is preferably a peptide linker in the context of the present invention. The term "peptide linker" as used herein refers to a peptide comprising one or more amino acid residues. More specifically, the term "peptide linker" as used herein refers to a peptide capable of connecting two variable proteins and / or domains, such as a Circoviridae virus capsid protein and a protein or fragment thereof encoded by the genome of a virus other than a Circoviridae virus.

[0025] In certain preferred embodiments, the Circoviridae viral capsid protein is linked to the heterologous protein or fragment thereof via a linker moiety, wherein: - the Circoviridae virus capsid protein is linked to the linker moiety via a peptide bond between the N-terminal amino acid residue of the linker moiety and the C-terminal amino acid residue of the capsid protein; - the linker moiety is linked to the heterologous protein or fragment thereof via a peptide bond between the N-terminal amino acid residue of the heterologous protein or fragment thereof and the C-terminal amino acid residue of the linker moiety. In addition, it may be preferable that the Circoviridae virus capsid protein is linked to a heterologous protein or a fragment thereof via a peptide bond between the C-terminal amino acid residue of the Circoviridae virus capsid protein and the N-terminal amino acid residue of the heterologous protein or a fragment thereof.

[0026] It will be understood that the polypeptides of the present invention are, in particular, fusion proteins. As used herein, the term "fusion protein" refers to a protein formed by fusing (i.e., linking) all or part of two or more non-identical polypeptides. Typically, fusion proteins are made using recombinant DNA techniques by linking polynucleotides encoding two or more polypeptides end-to-end. More specifically, the term "fusion protein" thus refers to a protein translated from a nucleic acid transcript made by combining a first nucleic acid sequence encoding a first polypeptide and at least a second nucleic acid encoding a second polypeptide, where the fusion protein is not a naturally occurring protein. A nucleic acid construct may encode two or more polypeptides linked in the fusion protein.

[0027] In another preferred embodiment, the present invention relates to a polypeptide, in particular a polypeptide as mentioned above, said polypeptide having the formula xyz, wherein: x consists of or comprises a Circoviridae virus capsid protein; y is a linker moiety, z is a heterologous protein or a fragment thereof The present invention provides a polypeptide that is a fusion protein of It should be understood that the formula xyz particularly means that the C-terminal amino acid residue of the capsid protein is linked to the linker moiety, preferably via a peptide bond with the N-terminal amino acid residue of the linker moiety, and that the N-terminal amino acid residue of the heterologous protein or fragment thereof is linked to the linker moiety, preferably via a peptide bond with the C-terminal amino acid residue of the linker moiety.

[0028] The Circoviridae virus referred to herein is preferably selected from the group consisting of Porcine Circovirus Type 2 (PCV2), Bat-Associated Circovirus 2 (BACV2) and Beak and Feather Disease Virus (BFDV). In one embodiment of the present invention, the Circoviridae virus referred to herein is PCV2. The PCV2 is preferably selected from the group consisting of PCV2 subtype a (PCV2a) and PCV2 subtype d (PCV2d). In a preferred embodiment, the Circoviridae capsid protein, as referred to herein, is selected from the group consisting of PCV2 ORF2 protein, BACV2 capsid protein and BFDV capsid protein. In certain preferred embodiments of the present invention, the Circoviridae capsid protein referred to herein is the PCV2 ORF2 protein.

[0029] The PCV2 ORF2 protein is preferably selected from the group consisting of PCV2 subtype a (PCV2a) ORF2 protein and PCV2 subtype d (PCV2d) ORF2 protein. In another preferred embodiment, the Circoviridae capsid protein, as described herein, is a bat-associated circovirus 2 (BACV2) capsid protein. In a further preferred embodiment, the Circoviridae capsid protein, as referred to herein, is a Beak and Feather Disease Virus (BFDV) capsid protein.

[0030] In certain preferred embodiments, the Circoviridae capsid proteins described herein comprise or consist of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. According to a further preferred embodiment, a heterologous protein or fragment thereof, as referred to herein, comprises or consists of an amino acid sequence that is at least 50 amino acid residues in length. Preferably, a heterologous protein or fragment thereof, as referred to herein, comprises or consists of an amino acid sequence that is at least 100 amino acid residues in length, most preferably at least 150 amino acid residues in length. In particular, the heterologous protein or fragment thereof referred to herein comprises or consists of an amino acid sequence that is 50 to 1000 amino acid residues in length, preferably 100 to 500 amino acid residues in length, and most preferably, the heterologous protein or fragment thereof is 150 to 250 amino acid residues in length.

[0031] The heterologous protein or fragment thereof as referred to herein is preferably encoded by the genome of a pathogen, in particular a virus other than a Circoviridae virus. In one non-limiting example, the pathogen is a rotavirus. Preferably, the heterologous protein or fragment thereof is a rotavirus protein domain or a rotavirus protein as described herein. In particular, the heterologous protein or fragment thereof described herein is a rotavirus VP8 protein domain or a fragment thereof. It is particularly preferred if the heterologous protein or fragment thereof comprises or is an immunogenic fragment of the rotavirus VP8 protein.

[0032] In a most preferred embodiment, the present invention comprises: - a polypeptide, in particular a fusion peptide, comprising a Circoviridae virus capsid protein linked to an immunogenic fragment of the rotavirus VP8 protein; and / or - the expression xyz(in the expression, x consists of or comprises a Circoviridae virus capsid protein; y is a linker moiety, z is an immunogenic fragment of the rotavirus VP8 protein) Fusion protein Regarding. The term "VP8 protein" as used herein refers to "VP8 domain", "VP8" which is frequently used in connection with rotavirus, * " or "VP8 fragment of VP4" and relates to the N-terminal trypsin cleavage product of rotavirus VP4.

[0033] The term "immunogenic fragment" is understood to refer specifically to a fragment of a protein that at least partially retains the immunogenicity of the protein from which it is derived. Thus, an "immunogenic fragment of a rotavirus VP8 protein" is understood to specifically refer to a fragment of a rotavirus VP8 protein that at least partially retains the immunogenicity of the full-length VP8 protein. In a preferred embodiment, an immunogenic fragment of a rotavirus VP8 protein, as referred to herein, is preferably capable of inducing an immune response against rotavirus in a subject to which said immunogenic fragment of a rotavirus VP8 protein is administered. In another preferred embodiment, the immunogenic fragment of the rotavirus VP8 protein is a polypeptide that is 50 to 200, preferably 140 to 190, amino acid residues in length. The rotavirus referred to herein is preferably selected from the group consisting of rotavirus A and rotavirus C. Therefore, the immunogenic fragment of a rotavirus VP8 protein referred to herein is preferably selected from the group consisting of an immunogenic fragment of a rotavirus A VP8 protein and an immunogenic fragment of a rotavirus C VP8 protein.

[0034] According to another preferred embodiment, the rotavirus referred to herein is a porcine rotavirus. In a particularly preferred embodiment, the rotavirus referred to herein is rotavirus A. Accordingly, an immunogenic fragment of a rotavirus VP8 protein as referred to herein is preferably an immunogenic fragment of a rotavirus A VP8 protein. The terms "rotavirus A" and "rotavirus C", when referred to herein, relate to rotavirus A and rotavirus C, respectively, as defined by ICTV (summarized by Matthijnssens et al. Arch Virol 157:1177-1182 (2012)). In a further preferred embodiment, the immunogenic fragment of a rotavirus VP8 protein comprises the lectin-like domain of a rotavirus VP8 protein. When referred to herein, the "lectin-like domain of a rotavirus VP8 protein" is understood to preferably refer to the lectin-like domain of a rotavirus A VP8 protein.

[0035] The term "lectin-like domain of rotavirus VP8 protein" particularly refers to residues 65 to 224 of rotavirus VP8 protein, which correspond to the amino acid sequence consisting of amino acid residues 65 to 224 of rotavirus VP8 protein, respectively, wherein said amino acid residues 65 to 224 of rotavirus VP8 protein are preferably amino acid residues 65 to 224 of rotavirus A VP8 protein. Therefore, the "lectin-like domain of rotavirus VP8 protein" preferably consists of the amino acid sequence of amino acid residues 65 to 224 of rotavirus VP8 protein, particularly rotavirus A VP8 protein.

[0036] Preferably, the immunogenic fragment of rotavirus VP8 protein is an N-terminally extended lectin-like domain of rotavirus VP8 protein, wherein said N-terminal extension is 1 to 20 amino acid residues in length, in particular 5 to 15 amino acid residues in length. Most preferably, the immunogenic fragment of rotavirus VP8 protein is an N-terminally extended lectin-like domain of rotavirus VP8 protein, wherein said N-terminal extension is 8 amino acid residues in length. The amino acid residues of the N-terminal extension are preferably individual lengths of amino acid sequence adjacent to the N-terminal amino acid residues of the lectin-like domain in the amino acid sequence of the rotavirus VP8 protein. Therefore, in a particular aspect, an immunogenic fragment of a rotavirus VP8 protein, as referred to herein, preferably consists of the amino acid sequence of amino acid residues 60 to 224, amino acid residues 59 to 224, amino acid residues 58 to 224, amino acid residues 57 to 224, amino acid residues 56 to 224, amino acid residues 55 to 224, amino acid residues 54 to 224, amino acid residues 53 to 224, amino acid residues 52 to 224, amino acid residues 51 to 224, amino acid residues 50 to 224, or amino acid residues 49 to 224 of a rotavirus VP8 protein, in particular a rotavirus A protein.

[0037] Most preferably, an immunogenic fragment of a rotavirus VP8 protein, as referred to herein, consists of the amino acid sequence of rotavirus VP8 protein, in particular, amino acid residues 57 to 224 of rotavirus A protein. The above numbering of amino acid residues (e.g., "65-224" or "57-224") preferably refers to the amino acid sequence of a wild-type rotavirus VP8 protein, in particular a wild-type rotavirus A VP8 protein. The wild-type rotavirus VP8 protein is preferably the protein set forth in SEQ ID NO:5. According to a further preferred embodiment, the rotavirus referred to herein is a rotavirus selected from the group consisting of genotype P[6] rotavirus, genotype P[7] rotavirus, and genotype P

[13] rotavirus, in particular rotavirus A. Accordingly, the immunogenic fragment of a rotavirus VP8 protein referred to herein is preferably selected from the group consisting of an immunogenic fragment of a genotype P[6] rotavirus VP8 protein, an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, and an immunogenic fragment of a genotype P

[13] rotavirus VP8 protein, in particular selected from the group consisting of an immunogenic fragment of a genotype P[6] rotavirus A VP8 protein, an immunogenic fragment of a genotype P[7] rotavirus A VP8 protein, and an immunogenic fragment of a genotype P

[13] rotavirus A VP8 protein.

[0038] The terms "genotype P[6] rotavirus," "genotype P[7] rotavirus," "genotype P

[13] rotavirus," and "genotype P

[23] rotavirus," as used herein, particularly relate to the established VP4(P) genotype classification of rotaviruses (e.g., P[6], P[7], P

[13] , or P

[23] ) as described in Estes and Kapikian. Rotaviruses. In: Knipe, D. M.; Howley, P. M. Fields Virology, 5th ed.; Wolters Kluwer / Lippincott Williams & Wilkins Health: Philadelphia, PA, USA (2007); Gorziglia et al. Proc Natl Acad Sci U S A. 87(18):7155-9 (1990).

[0039] Most preferably, the rotavirus referred to herein is a genotype P[7] rotavirus, and therefore, the immunogenic fragment of a rotavirus VP8 protein referred to herein is most preferably an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, in particular an immunogenic fragment of a genotype P[7] rotavirus A VP8 protein. The rotavirus VP8 protein referred to herein most preferably comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to the sequence of SEQ ID NO: 5. The lectin-like domain of the rotavirus VP8 protein, as referred to herein, preferably comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with the sequence of SEQ ID NO: 6. In one example, an immunogenic fragment of a rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with the sequence of SEQ ID NO: 7. In another preferred embodiment, the immunogenic fragment of a rotavirus VP8 protein consists of or is a portion of a rotavirus VP8 protein, in particular a consensus sequence of a portion of a rotavirus A VP8 protein.

[0040] As used herein, the term "consensus sequence" particularly refers to a sequence formed from the amino acids (or nucleotides) that occur most frequently in a family of related sequences (see, e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of proteins, each position in the consensus sequence is occupied by the amino acid that occurs most frequently at that position in the family. The term "consensus sequence" therefore represents a putative amino acid sequence (or nucleotide sequence). A consensus sequence represents multiple similar sequences. Each position in a consensus sequence corresponds to the amino acid residue (or nucleotide base) that occurs most frequently at that position as determined by aligning three or more sequences.

[0041] Preferably, the consensus sequence of a portion of the rotavirus VP8 protein, as referred to herein, is: - translating the plurality of nucleotide sequences encoding portions of the rotavirus VP8 protein into amino acid sequences; - aligning said amino acid sequence with known rotavirus VP8 proteins, preferably by using the MUSCLE sequence alignment software UPGMB clustering and default gap penalty parameters; - subjecting the aligned sequences to phylogenetic analysis and generating a neighbor-joining phylogenetic reconstruction based on rotavirus VP8 protein sequences, in particular importing the aligned amino acid sequences into MEGA7 software for phylogenetic analysis and generating a neighbor-joining phylogenetic reconstruction based on rotavirus VP8 protein sequences, - calculating the optimal tree using the Poisson correction method with phylogenetic bootstrap tests (n=100); - drawing a scaled optimal tree across all 170 positions in units of amino acid substitutions per site with branch lengths equal to the evolutionary distance; - considering as significant nodes those with bootstrap cluster associations higher than 70%; - designating as clusters nodes that have a distance of approximately 10% and a bootstrap cluster association of greater than 70%; and - generating a consensus sequence by selecting clusters and identifying the maximum frequency per aligned position within the clusters; and - optionally selecting amino acid residues based on reported epidemiological data in conjunction with predefined product protection profiles when an equivalent proportion of amino acids is observed at the aligned positions. It can be obtained by a method comprising:

[0042] For example, in this context, an immunogenic fragment of a rotavirus VP8 protein preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 9. In a further preferred embodiment, the rotavirus referred to herein is rotavirus C. According to this embodiment, the immunogenic fragment of a rotavirus VP8 protein is preferably an immunogenic fragment of a rotavirus C VP8 protein. In the context of this embodiment, an immunogenic fragment of a rotavirus VP8 protein preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with the sequence of SEQ ID NO: 10.

[0043] According to the present invention, the heterologous protein or fragment thereof is therefore preferably an immunogenic fragment of the rotavirus A VP8 protein, in particular any of the immunogenic fragments of the rotavirus A VP8 protein described herein, or - a portion of a rotavirus VP8 protein, for example a portion of a rotavirus A VP8 protein, preferably a consensus sequence of any of the immunogenic fragments of a rotavirus VP8 protein described herein in the context of the consensus sequence, or - an immunogenic fragment of the rotavirus C VP8 protein, in particular any of the immunogenic fragments of the rotavirus C VP8 protein described herein. It consists of or is.

[0044] In certain preferred embodiments, a heterologous protein or fragment thereof, as described herein, is a polypeptide consisting of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10. The linker moiety referred to herein, particularly the peptide linker described in the context of the present invention, is preferably an amino acid sequence having a length of 1 to 50 amino acid residues, particularly an amino acid sequence having a length of 3 to 20 amino acid residues. For example, the linker moiety may be a peptide linker having a length of 3, 8, or 10 amino acid residues. Depending on the purpose, a short linker may be desirable to reduce the risk of proteolysis between the fusion protein partners. Thus, the peptide linkers described in the context of the present invention preferably each have a length of 1 to 5 amino acid residues, more preferably 2 to 4 amino acid residues, and most preferably 3 amino acid residues.

[0045] Preferably, the linker moieties described herein comprise or consist of an amino acid sequence having at least 66%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or especially 100% sequence identity to a sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13. According to a further aspect, the polypeptide of the invention is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or in particular 100% sequence identity to a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:21. Preferably, the polypeptide of the present invention is a protein comprising or consisting of a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:21.

[0046] It is understood that the expressions "consisting of an amino acid sequence" or "consists of an amino acid sequence", respectively, as used herein also relate to any co-translational and / or post-translational modification(s) of an amino acid sequence that are particularly affected by the cell in which the protein or protein domain is expressed. Thus, the expressions "consisting of an amino acid sequence" or "consists of an amino acid sequence", respectively, as used herein also cover amino acid sequences that have one or more modifications that are brought about by the cell in which the protein or protein domain is expressed, in particular modifications of amino acid residues that are brought about during protein biosynthesis and / or protein processing, preferably selected from the group consisting of glycosylation, phosphorylation and acetylation.

[0047] With regard to the term "at least 90%", when referred to in the context of the present invention, it is understood that said term preferably relates to "at least 91%", more preferably "at least 92%", even more preferably "at least 93%", or especially "at least 94%". With regard to the term "at least 95%", when referred to in the context of the present invention, it is understood that said term preferably relates to "at least 96%", more preferably "at least 97%", even more preferably "at least 98%", or especially "at least 99%".

[0048] With regard to the term "at least 99%", when referred to in the context of the present invention, it is understood that said term preferably relates to "at least 99.2%", more preferably "at least 99.4%", even more preferably "at least 99.6%", or especially "at least 99.8%". It is understood that the term "having 100% sequence identity" as used herein is equivalent to the term "identical."

[0049] Percent sequence identity has an art-recognized meaning, and there are many methods for measuring identity between two polypeptide or polynucleotide sequences. See, e.g., Lesk, Ed., Computational Molecular Biology, Oxford University Press, New York, (1988); Smith, Ed., Biocomputing: Informatics And Genome Projects, Academic Press, New York, (1993); Griffin & Griffin, Eds., Computer Analysis Of Sequence Data, Part I, Humana Press, New Jersey, (1994); von Heinje, Sequence Analysis In Molecular Biology, Academic Press, (1987); and Gribskov & Devereux, Eds., Sequence Analysis Primer, M Stockton Press, New York, (1991). Methods for aligning polynucleotides or polypeptides are codified in computer programs including the GCG program package (Devereux et al., Nuc. Acids Res. 12:387 (1984)), BLASTP, BLASTN, FASTA (Atschul et al., J. Molec. Biol. 215:403 (1990)), and the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711), which uses the local homology algorithm of Smith and Waterman (Adv. App. Math., 2:482-489 (1981)).For example, the computer program ALIGN, which utilizes the FASTA algorithm, can be used with an affine gap search with a gap opening penalty of -12 and a gap extension penalty of -2. For purposes of the present invention, nucleotide sequences are aligned using the Clustal W method in MegAlign software version 11.1.0(59),419 by DNASTAR Inc., using the default multiple alignment parameters set in this program (gap penalty = 15.0, gap length penalty = 6.66, and delayed mismatch (%) = 30%, DNA transfer weight = 0.50, and DNA weight matrix = IUB), and protein / amino acid sequences are aligned using the Clustal W method in MegAlign software version 11.1.0(59),419 by DNASTAR Inc., using the default multiple alignment parameters set in this program (gap penalty = 10.0, gap length penalty = 0.2, and Gonnet series protein weight matrix with delayed mismatch (%) = 30%).

[0050] As used herein, the term "sequence identity to the sequence of SEQ ID NO:X" is specifically understood to be equivalent to the terms "sequence identity to the sequence of SEQ ID NO:X over the length of SEQ ID NO:X" or "sequence identity to the sequence of SEQ ID NO:X over the entire length of SEQ ID NO:X," respectively. In this context, "X" is any integer selected from 1 to 33, such that "SEQ ID NO:X" represents any of the SEQ ID NOs referred to herein. The expression "the group consisting of SEQ ID NO:[...], ... and SEQ ID NO:[...]" when used herein is interchangeable with "the group consisting of the sequence SEQ ID NO:[...], ... and the sequence SEQ ID NO:[...]". "[...]" in this context is a placeholder for the sequence number. For example, the expression "the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10" is interchangeable with "the group consisting of the sequence SEQ ID NO:7, the sequence SEQ ID NO:8, the sequence SEQ ID NO:9 and the sequence SEQ ID NO:10".

[0051] In a most preferred embodiment, the polypeptide of the present invention is capable of assembling with a plurality of identical polypeptides to form a virus-like particle. The expressions "assemble" or, respectively, "assemble with a plurality of identical polypeptides", when referred to herein, are understood to be equivalent in particular to "self-assembly". The term "multiple identical polypeptides" as used herein is particularly interchangeable with "multiple polypeptides consisting of the same amino acid sequence." According to a further aspect, there is provided a virus-like particle, which comprises a polypeptide of the invention or is composed of a plurality of polypeptides of the invention. Said virus-like particle, hereinafter also referred to as "virus-like particle according to the invention", is preferably an isolated virus-like particle.

[0052] "Virus-like particle" in the context of the present invention refers in particular to a particle structure that does not contain a viral genome, which structure is formed by the self-assembly of several proteins, where at least some of the proteins forming the structure are identical to or derived from viral structural proteins (capsid proteins), such as proteins comprising the amino acid sequence of a Circoviridae virus capsid protein, and the structure is preferably formed by at least 60 proteins.

[0053] Preferably, a heterologous protein or fragment thereof constituted by a polypeptide of the present invention, for example an immunogenic fragment of the rotavirus VP8 protein, as described herein, is displayed on the outer surface of a virus-like particle of the present invention. The present invention further provides an immunogenic composition comprising a polypeptide of the invention and / or a virus-like particle of the invention, wherein said immunogenic composition is hereinafter also referred to as "immunogenic composition of the invention". Immunogenic compositions of the invention preferably comprise a polypeptide of the invention at a concentration of at least 100 nM, preferably at least 250 nM, more preferably at least 500 nM, most preferably at least 1 μM. According to another preferred embodiment, the immunogenic composition of the present invention contains the polypeptide of the present invention at a concentration of 100 nM to 50 μM, preferably 250 nM to 25 μM, and most preferably 1 to 10 μM. In particular, 1 mL, or in some cases 2 mL, of the immunogenic composition of the invention is administered to a subject. Thus, the dose of the immunogenic composition of the invention administered to a subject preferably has a volume of 1 mL or 2 mL. Preferably, one or two doses of the immunogenic composition are administered to the subject.

[0054] The immunogenic compositions of the present invention are preferably administered systemically or locally. Suitable routes of administration commonly used are parenteral or oral administration, for example, intramuscular, intradermal, intravenous, intraperitoneal, subcutaneous, intranasal, and inhalation. However, depending on the nature and mechanism of action of the compound, the immunogenic compositions may also be administered by other routes. It is most preferred that the immunogenic compositions are administered intramuscularly. The immunogenic compositions of the invention preferably further comprise a pharmaceutically or veterinarily acceptable carrier or excipient. As used herein, "pharmaceutically or veterinarily acceptable carriers" includes any and all solvents, dispersion media, coatings, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, absorption retarding agents, etc. In some preferred embodiments, particularly those comprising lyophilized immunogenic compositions, stabilizers for use in the present invention include stabilizers for lyophilization or freeze-drying.

[0055] In some embodiments, the immunogenic compositions of the invention contain an adjuvant. As used herein, "adjuvants" may include aluminum hydroxide and aluminum phosphate, saponins such as Quil A, QS-21 (Cambridge Biotech Inc., Cambridge MA), and GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, AL), water-in-oil emulsions, oil-in-water emulsions, and water-in-oil-in-water emulsions. The emulsions may be based, in particular, on light liquid paraffin oil (European Pharmacopoeia type); isoprenoid oils such as squalane or squalene; oils obtained from the oligomerization of alkenes, in particular isobutene or decene; esters of acids or alcohols containing linear alkyl groups, more particularly vegetable oils, ethyl oleate, propylene glycol di(caprylate / caprate), glyceryl tri(caprylate / caprate), or propylene glycol dioleate; and esters of branched fatty acids or alcohols, in particular isostearate esters. The oil is used in combination with an emulsifier to form an emulsion. The emulsifier is preferably a nonionic surfactant, particularly sorbitan, mannide (e.g., anhydrous mannitol oleate), glycol, polyglycerol, propylene glycol, and esters of oleic acid, isostearic acid, ricinoleic acid, or hydroxystearic acid, which may be ethoxylated, and a polyoxypropylene-polyoxyethylene copolymer block, particularly Pluronic products, especially L121. See Hunter et al., The Theory and Practical Application of Adjuvants (Ed. Stewart-Tull, DES), John Wiley and Sons, NY, pp. 51-94 (1995) and Todd et al., Vaccine 15:564-570 (1997).An exemplary adjuvant is the SPT emulsion described on page 147 of "Vaccine Design, The Subunit and Adjuvant Approach" edited by M. Powell and M. Newman, Plenum Press, 1995, or emulsion MF59 described on page 183 of the same book.

[0056] Further examples of adjuvants are compounds selected from polymers of acrylic acid or methacrylic acid and copolymers of maleic anhydride and alkenyl derivatives. Advantageous adjuvant compounds are crosslinked polymers of acrylic acid or methacrylic acid, particularly crosslinked with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Those skilled in the art can also refer to U.S. Pat. No. 2,909,462, which describes such acrylic polymers crosslinked with polyhydroxylated compounds having at least three hydroxyl groups, preferably not more than eight, in which at least three hydroxyl hydrogen atoms are replaced by unsaturated aliphatic groups having at least two carbon atoms. Preferred groups are those containing 2 to 4 carbon atoms, such as vinyl, allyl, and other ethylenically unsaturated groups. The unsaturated groups may themselves contain other substituents, such as methyl. Particularly suitable are products sold under the name CARBOPOL® (BF Goodrich, Ohio, USA). They are cross-linked with allyl sucrose or allyl pentaerythritol. Among them, Carbopol® 974P, 934P and 971P may be mentioned. The use of CARBOPOL® 971P is most preferred. Among the copolymers of maleic anhydride and alkenyl derivatives is the copolymer EMA (Monsanto), which is a copolymer of maleic anhydride and ethylene. Dissolution of these polymers in water results in an acid solution that is preferably neutralized to physiological pH to give an adjuvant solution that can be incorporated into the immunogenic, immunological or vaccine composition itself.

[0057] Additional suitable adjuvants from which the adjuvant may be selected include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), block copolymers (CytRx, Atlanta, GA), SAF-M (Chiron, Emeryville, CA), monophosphoryl lipid A, avridine lipid-amine adjuvant, heat-labile enterotoxin from Escherichia coli (recombinant or otherwise), cholera toxin, IMS1314, or muramyl dipeptide, or naturally occurring or recombinant cytokines or analogs thereof, or stimulators of endogenous cytokine release, among many others. It is expected that the adjuvant may be added in an amount of about 100 μg to about 10 mg per dose, preferably about 100 μg to about 10 mg per dose, more preferably about 500 μg to about 5 mg per dose, even more preferably about 750 μg to about 2.5 mg per dose, and most preferably about 1 mg per dose. Alternatively, the adjuvant may be added at a concentration of about 0.01 to 50% of the volume of the final product, preferably about 2% to 30%, more preferably about 5% to 25%, even more preferably about 7% to 22%, and most preferably 10% to 20%.

[0058] "Diluents" may include water, saline, dextrose, ethanol, glycerol, etc. Isotonic agents may include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin and alkali salts of ethylenediaminetetracetic acid, among others.

[0059] According to a particularly preferred aspect, the present invention also provides an immunogenic composition, in particular an immunogenic composition of the invention, wherein the immunogenic composition comprises: - a polypeptide of the invention, and - a pharmaceutically or veterinarily acceptable carrier or excipient, and - optionally, an adjuvant It comprises or consists of: Adjuvants in the context of the present invention are preferably selected from the group consisting of emulsified oil-in-water adjuvants and carbomers. The term "immunogenic composition" refers to a composition comprising at least one antigen that elicits an immunological response in a host to which the immunogenic composition is administered. Such an immunological response can be a cellular immune response and / or an antibody-mediated immune response to the immunogenic composition of the present invention. A host is also described as a "subject." Preferably, either a host or a subject described or referred to herein is an animal. The term "animal" as used herein particularly relates to mammals, preferably to Sus scrofa, more preferably to pigs, most preferably to piglets.

[0060] Typically, an "immunological response" includes, but is not limited to, one or more of the following effects: the production or activation of antibodies, B cells, helper T cells, suppressor T cells, and / or cytotoxic T cells and / or gamma-delta T cells specifically directed against one or more antigens comprised in the immunogenic composition of the invention. Preferably, the host mounts either a protective immunological response or a therapeutic response. A "protective immunological response" is demonstrated by either a reduction or absence of one or more clinical signs normally exhibited by an infected host, a more rapid recovery time and / or a shorter duration of infection, or a lower pathogen titer in the tissues or body fluids or excretions of the infected host.

[0061] "Pathogen" or "particular pathogen" as referred to herein particularly relates to the pathogen from which the heterologous protein or fragment thereof is derived. For example, the pathogen as referred to herein is a pathogenic virus, such as a rotavirus, particularly rotavirus A or rotavirus C.

[0062] When the host mounts a protective immunological response such that resistance to new infection is enhanced and / or the clinical severity of disease is reduced, the immunogenic composition is described as a "vaccine." "Antigen," as used herein, refers to a component that elicits an immunological response in a host, including but not limited to, an immunological composition or vaccine of interest that contains such antigen or an immunologically active component thereof. In particular, the term "antigen," as used herein, refers to a protein or protein domain that, when administered to a host, can elicit an immunological response in the host.

[0063] The term "treatment and / or prevention" refers to reducing the occurrence of a particular pathogen infection in a population, or reducing the severity of one or more clinical signs caused by or associated with a particular pathogen infection. Thus, the term "treatment and / or prevention" refers to reducing the number of animals in a population that become infected with a particular pathogen (=reducing the occurrence of a particular pathogen infection), or reducing the severity of one or more clinical signs normally associated with or caused by infection by a pathogen in a group of animals whose animals have received an effective amount of an immunogenic composition provided herein, compared to a group of animals whose animals have not received such immunogenic composition. "Treatment and / or prevention" generally involves administration of an effective amount of a polypeptide of the invention or an immunogenic composition of the invention to a subject or a population of subjects in need of or who may benefit from such treatment / prevention. The term "treatment" refers to administration of an effective amount of an immunogenic composition at a time when subjects or at least some animals in a population have already been infected with such a pathogen and such animals are already showing some clinical signs caused by or associated with such pathogen infection. The term "prevention" refers to administration to a subject prior to any infection of such subjects with a pathogen, or at least when all animals in such an animal or group of animals are not showing one or more clinical signs caused by or associated with infection by such pathogen.

[0064] The term "effective amount," as used herein, refers to, but is not limited to, an amount of an antigen, particularly a polypeptide of the present invention, that induces or is capable of inducing an immune response in a subject. Such an effective amount can reduce the occurrence of a specific pathogen infection in a population or reduce the severity of one or more clinical signs of a specific pathogen infection. Preferably, the occurrence or severity of one or more clinical signs is reduced by at least 10%, more preferably at least 20%, even more preferably at least 30%, even more preferably at least 40%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95%, compared to either untreated or subjects treated with an immunological composition available prior to the present invention but subsequently infected with a specific pathogen.

[0065] The term "clinical signs," as used herein, refers to signs of infection in a subject from a particular pathogen. Clinical signs of infection depend on the pathogen selected. Examples of such clinical signs include, but are not limited to, diarrhea, vomiting, fever, abdominal pain, and dehydration. A reduction in the appearance or severity of one or more clinical signs caused by or associated with a particular pathogen infection in a subject can be achieved by administering to the subject one or more doses of an immunogenic composition of the invention.

[0066] The term "reducing fecal shedding" refers to, but is not limited to, a reduction in the number of RNA copies of a pathogenic virus, such as rotavirus, per mL of feces or the number of plaque-forming colonies per deciliter of feces, in the feces of a subject receiving a composition of the present invention by at least 50% compared to a subject who has not received the composition and may become infected. More preferably, fecal shedding levels are reduced by at least 90%, preferably at least 99.9%, more preferably at least 99.99%, and even more preferably at least 99.999% in subjects receiving a composition of the present invention. The term "fecal shedding," as used herein, is used in accordance with its plain and ordinary meaning in medicine and virology and refers to the production and release of virus from a subject's cells into the environment from an infected subject via the subject's feces.

[0067] The polypeptides of the present invention are preferably recombinant proteins, in particular recombinant baculovirus-expressed proteins. The term "recombinant protein," as used herein, particularly refers to a protein produced by recombinant DNA techniques, where typically DNA encoding the expressed protein is inserted into a suitable expression vector, which is then used to transform, or in the case of a viral vector, infect, a host cell to produce the heterologous protein. Thus, the term "recombinant protein," as used herein, particularly refers to a protein molecule that is expressed from a recombinant DNA molecule. "Recombinant DNA molecule," as used herein, refers to a DNA molecule that is comprised of segments of DNA joined together by molecular biological techniques. Suitable systems for the production of recombinant proteins include, but are not limited to, insect cells (e.g., baculovirus), prokaryotic systems (e.g., Escherichia coli), fungi (e.g., Myceliophthora thermophile, Aspergillus oryzae, Ustilago maydis), yeast (e.g., Saccaromyces cerevisiae, Pichia pastoris), mammalian cells (e.g., Chinese hamster ovary, HEK293), plants (e.g., safflower), algae, avian cells, amphibian cells, fish cells, and cell-free systems (e.g., rabbit reticulocyte lysate).

[0068] According to another aspect, the present invention provides a polynucleotide comprising a sequence encoding a polypeptide of the present invention, wherein said polynucleotide, hereinafter also referred to as a "polynucleotide according to the present invention", is preferably an isolated polynucleotide. Preferably, the polynucleotide according to the invention comprises a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or especially 100% sequence identity to a sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29.

[0069] Production of the polynucleotides described herein is within the skill in the art and can be carried out according to recombinant techniques described in, among others, Sam brook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Amusable, et al., 2003, Current Protocols In Molecular Biology, Greene Publishing Associates & Wiley Interscience, NY; Innis et al. (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1994, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference. In a still further aspect, the present invention provides a vector containing a polynucleotide encoding a polypeptide of the present invention.

[0070] "Vector" and "vector containing a polynucleotide encoding a polypeptide of the invention", for purposes of the present invention, refer to a suitable expression vector, preferably a baculovirus expression vector, which is then used to transfect, or in the case of a baculovirus expression vector, infect a host cell so as to produce the protein or polypeptide encoded by the DNA. Vectors and methods for making and / or using vectors (or recombinants) for expression are described in U.S. Patent Nos. 4,603,112, 4,769,330, 5,174,993, 5,505,941, 5,338,683, 5,494,807, 4,722,848, 5,942,235, 5,364,773, 5,762,938, 5,770,212, 5,942,235, and 382,425; PCT Publication Nos. WO 94 / 16716, WO 96 / 39491, and WO 95 / 30018; Paoletti, "Applications of pox virus vectors to Vaccination: An update, PNAS USA 93: 11349-11353, October 1996; Moss, "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," PNAS USA 93: 11341-11348, October 1996; Smith et al., U.S. Pat. No. 4,745,051 (recombinant baculovirus); Richardson, CD (Editor), Methods in Molecular Biology 39, "Baculovirus Expression Protocols" (1995 Humana Press Inc.); Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Molecular and Cellular Biology, December 1983, Vol. 3, No. 12, pp. 2156-2165; Pennock et al., "Strong and Regulated Expression of Escherichia coli B-Galactosidase in Infected Cells with a Baculovirus Vector," Molecular and Cellular Biology, March 1984, Vol. 4, No. 3, p. 406; European Patent Application No. 0370573; U.S. Application No. 920,197, filed October 16, 1986; European Patent Application Publication No. 265785; U.S. Patent No. 4,769,331 (recombinant herpesvirus); Roizman, "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," PNAS USA 93:11307-11312, October 1996;Andreansky et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," PNAS USA 93: 11313-11318, October 1996;Robertson et al., "Epstein-Barr virus vectors for gene delivery to B lymphocytes", PNAS USA 93: 11334-11340, October 1996;Frolov et al., "Alphavirus-based expression vectors: Strategies and applications," PNAS USA 93: 11371-11377, October 1996; Kitson et al., J. Virol. 65, 3068-3075, 1991; U.S. Patent Nos. 5,591,439 and 5,552,143; WO 98 / 00166; U.S. Application Nos. 08 / 675,556 and 08 / 675,566, both filed July 3, 1996, and allowed (recombinant adenovirus); Grunhaus et al., 1992, "Adenovirus as cloning vectors," Seminars in Virology (Vol. 3) pp. 237-52, 1993; Ballay et al., EMBO Journal, vol. 4, pp. 3861-65, Graham, Tibtech 8, 85-87, April, 1990;Prevec et al., J.Gen Virol.70, 42434;PCT International Publication No. 91 / 11525;Felgner et al.(1994), J.Biol.Chem.269, 2550-2561, Science, 259: 1745-49, 1993; and McClements et al., “Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease”, PNAS USA 93: 11414-11420, October 1996; and U.S. Patent Nos. 5,591,639, 5,589,466, and 5,580,859, as well as WO 90 / 11092, WO 93 / 19183, WO 94 / 21797, WO 95 / 11307, WO 95 / 20660; Tang et al., Nature and Furth et al., especially regarding DNA expression vectors., Analytical Biochemistry, or methods analogous thereto. See also WO 98 / 33510; Ju et al., Diabetologia, 41: 736-739, 1998 (lentiviral expression systems); Sanford et al., U.S. Pat. No. 4,945,050; Fischbach et al. (Intracel); WO 90 / 01543; Robinson et al., Seminars in Immunology, vol. 9, pp. 271-283 (1997) (DNA vector systems); Szokka et al., U.S. Pat. No. 4,394,448 (method of inserting DNA into living cells); McCormick et al., U.S. Pat. No. 5,677,178 (use of cytopathic viruses); and U.S. Pat. No. 5,928,913 (vectors for gene delivery), as well as other documents cited herein.

[0071] Preferred viral vectors include baculoviruses such as BaculoGold (BD Biosciences Pharmingen, San Diego, CA), particularly if the producer cells are insect cells. While the baculovirus expression system is preferred, it will be understood by those skilled in the art that other expression systems, including those described above, will work for the purposes of the present invention, i.e., for expression of recombinant proteins.

[0072] Therefore, the present invention also provides a baculovirus containing a polynucleotide comprising a sequence encoding a polypeptide of the present invention. Said baculovirus, hereinafter also referred to as "a baculovirus according to the present invention", is preferably an isolated baculovirus. Furthermore, the present invention therefore also provides a plasmid, preferably an expression vector, comprising a polynucleotide comprising a sequence encoding a polypeptide of the invention. Said plasmid, hereinafter also referred to as "the plasmid according to the invention", is in particular an isolated plasmid. The present invention also provides a cell infected with and / or containing a baculovirus comprising a polynucleotide comprising a sequence encoding a polypeptide of the invention, or a plasmid, preferably an expression vector, comprising a polynucleotide comprising a sequence encoding a polypeptide of the invention. Said cell, hereinafter also referred to as "a cell according to the invention", is preferably an isolated cell.

[0073] The term "isolated" when used in reference to an isolated cell is a cell that exists by the hand of man apart from its natural environment and is therefore not a product of nature. In yet another aspect, the present invention relates to the use of a polypeptide of the invention, a baculovirus according to the invention, an immunogenic composition of the invention, a polynucleotide according to the invention, a virus-like particle according to the invention, a plasmid according to the invention, and / or a cell according to the invention for the preparation of a medicament, preferably a vaccine.

[0074] In this context, the present invention also provides a method for producing a polypeptide of the invention and / or a virus-like particle of the invention, said method comprising the step of infecting a cell, preferably an insect cell, with a baculovirus according to the invention. Furthermore, the present invention also provides a method for producing a polypeptide of the invention and / or a virus-like particle of the invention, said method comprising the step of transfecting a cell with a plasmid according to the invention. The polypeptides of the present invention are preferably expressed in amounts high enough for stable self-assembly of virus-like particles, which can then be used for vaccination. The term "vaccination" or "vaccinating", as used herein, means, but is not limited to, a process comprising the administration of an antigen, e.g., an antigen comprised in an immunogenic composition, to a subject, wherein said antigen, e.g., a polypeptide of the invention, when administered to a subject, induces or is capable of eliciting a protective immunological response in said subject. The present invention also provides a polypeptide of the present invention or an immunogenic composition of the present invention for use as a medicament, preferably as a vaccine.

[0075] In particular, the polypeptides of the present invention or the immunogenic compositions of the present invention are provided for use in methods for reducing or preventing one or more clinical signs or disease caused by infection with a pathogen, wherein the pathogen is preferably a pathogen of a species having a genome encoding a heterologous protein or a fragment thereof. When the pathogen is a virus, the polypeptides of the present invention or the immunogenic compositions of the present invention are provided for use in methods for reducing or preventing one or more clinical signs or disease caused by infection with the virus, wherein the virus is preferably a virus of a species having a genome encoding a heterologous protein or a fragment thereof. Thus, in a specific example, when the heterologous protein or a fragment thereof referred to herein is encoded by the genome of rotavirus A, the polypeptides of the present invention or the immunogenic compositions of the present invention are for use in methods for reducing or preventing one or more clinical signs, mortality, fecal shedding, or disease caused by infection with rotavirus A.

[0076] More specifically, a polypeptide of the invention or an immunogenic composition of the invention is provided for use in a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in a subject, or for use in a method of treating or preventing infection by rotavirus in a subject. Rotavirus infection, when referred to herein, refers in particular to infection by rotavirus A or rotavirus C. Furthermore, a polypeptide of the invention or an immunogenic composition of the invention is provided for use in a method for inducing an immune response against rotavirus in a subject.

[0077] According to another preferred embodiment, the polypeptide of the invention or the immunogenic composition of the invention comprises: in the subject, preferably simultaneously, A method for inducing an immune response against a pathogen of a species having a genome encoding a heterologous protein or fragment thereof; and A method for inducing an immune response against a Circoviridae virus, wherein the Circoviridae virus is preferably a virus of a species encoding the Circoviridae capsid protein. is provided for use in

[0078] In particular, the polypeptide of the invention or the immunogenic composition of the invention is provided for use in a method for inducing an immune response against rotavirus and PCV2 in a subject, preferably simultaneously. As used herein, the subject is preferably a mammal, such as a boar or a bovine, or an avian, such as a chicken. In particular, the subject is a pig, wherein the pig is preferably a piglet or a sow, such as a pregnant sow. Most preferably, in the context of inducing an immune response against rotavirus in a subject, the subject is a pregnant sow. In the context of reducing or preventing one or more clinical signs, mortality, or fecal shedding caused by rotavirus infection in a subject, or treating or preventing rotavirus infection in a subject, the subject is most preferably a piglet.

[0079] According to a preferred aspect, the polypeptide of the invention or the immunogenic composition of the invention is for use in a method for reducing or preventing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in piglets, wherein the piglets are suckled by a sow to which the immunogenic composition has been administered, preferably a sow to which the immunogenic composition has been administered while the sow is pregnant, in particular while the sow is pregnant with the piglets. Furthermore, the polypeptide of the present invention or the immunogenic composition of the present invention preferably comprises: - one or more clinical signs caused by infection with a pathogen of a species having a genome encoding a heterologous protein or a fragment thereof, and - one or more clinical signs caused by infection with a Circoviridae virus, the Circoviridae virus preferably being of a species that encodes said Circoviridae capsid protein. The present invention is for use in a method for reducing or preventing

[0080] When the pathogen is a virus, the polypeptide of the invention or the immunogenic composition of the invention is particularly preferably administered simultaneously with - one or more clinical signs caused by infection with a virus of a species whose genome encodes a heterologous protein or a fragment thereof, and - one or more clinical signs caused by infection with a Circoviridae virus, the Circoviridae virus preferably being of a species that encodes said Circoviridae capsid protein. The present invention is provided for use in a method for reducing or preventing In particular, the polypeptide of the invention or the immunogenic composition of the invention may - one or more clinical signs, mortality or fecal shedding caused by rotavirus infection, and - One or more clinical signs, mortality, or nasal discharge caused by PCV2 The present invention is provided for use in a method for reducing or preventing

[0081] Thus, in one particular example, when the Circoviridae capsid protein referred to herein is the PCV2 ORF2 protein and the heterologous protein or fragment thereof referred to herein is encoded by the genome of Rotavirus A: The polypeptide of the present invention or the immunogenic composition of the present invention comprises: A method for reducing or preventing one or more clinical signs, fecal shedding, or disease caused by infection with rotavirus A; and a method for reducing or preventing one or more clinical signs, nasal discharge, or disease caused by infection with PCV2. It is an immunogenic composition for use in

[0082] According to a further aspect, the polypeptide of the invention or the immunogenic composition of the invention is an immunogenic composition for use in a method for inducing an immune response against rotavirus and PCV2, preferably in pigs, in particular preferably in pregnant sows. Furthermore, the present invention relates to a method for treating or preventing rotavirus infection, reducing, preventing or treating one or more clinical signs, mortality or fecal shedding caused by rotavirus infection, or preventing or treating a disease caused by rotavirus infection, said method comprising the step of administering to a subject a polypeptide of the present invention or an immunogenic composition of the present invention. Also preferably provided is a method for inducing the production of rotavirus-specific antibodies in a pregnant sow, said method comprising the step of administering to said sow a polypeptide of the present invention or an immunogenic composition of the present invention.

[0083] Furthermore, the present invention provides a method for reducing or preventing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in piglets, said method comprising: - administering a polypeptide of the invention or an immunogenic composition according to the invention to a sow, and - the piglet is suckled by the sow. wherein the sow is preferably a sow that is particularly pregnant with the piglets. Preferably, the two methods are: - administering a polypeptide of the invention or an immunogenic composition according to the invention to a sow that is pregnant with piglets, - allowing the sow to give birth to the piglets; and - the piglet is suckled by the sow. Includes. Also provided is a method for reducing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in piglets, wherein the piglets are suckled by a sow to which a polypeptide of the invention or an immunogenic composition of the invention has been administered.

[0084] The one or more clinical signs, as referred to herein, are preferably: - diarrhea, - pathogen colonization, in particular colonization of a pathogen of a species having a genome encoding a heterologous protein or a fragment thereof, said pathogen colonization being preferably rotavirus colonization, - Lesions, especially gross lesions, and - Reduced average daily weight gain is selected from the group consisting of: According to one example, the one or more clinical signs referred to herein are rotavirus colonization of the intestine, particularly the small intestine. According to another example, the one or more clinical signs referred to herein are intestinal lesions, particularly macroscopic intestinal lesions.

[0085] According to another particularly preferred embodiment, the polypeptide of the invention or the immunogenic composition of the invention is prepared by the method described above, comprising the steps of: - the rotavirus infection is an infection with genotype P

[23] rotavirus and / or genotype P[7] rotavirus, - the rotavirus infection is an infection with genotype P

[23] rotavirus and / or genotype P[7] rotavirus, - the immune response against rotavirus is an immune response against genotype P

[23] rotavirus and / or genotype P[7] rotavirus, or - the rotavirus-specific antibodies are antibodies specific to genotype P

[23] rotavirus and / or genotype P[7] rotavirus, Preferably, the polypeptide of the present invention is any of the polypeptides of the present invention described herein comprising an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, or the immunogenic composition of the present invention comprises any of the polypeptides of the present invention described herein comprising an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, or the polypeptide or immunogenic composition administered in the method is or comprises any of the polypeptides of the present invention described herein comprising an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, More preferably, - the fragment consists of an amino acid sequence that has at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with the sequence of SEQ ID NO: 7, and / or - the polypeptide is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 14, The invention is for use in any of the methods. [Example]

[0086] The following examples are intended only to illustrate the present disclosure. They do not limit the scope of the claims in any way.

[0087] Example 1 Fusion protein design, production and testing: Building design: Exemplarily, fusion of a rotavirus A or C VP8 protein fragment to the C-terminus of the PCV2 ORF2 protein was tested. The PCV2 ORF2 DNA sequence used in the PCV2-VP8 fusion corresponds to the PCV2a sequence encoding the amino acid sequence of SEQ ID NO:1.

[0088] The rotavirus A VP4 sequence was originally obtained from a fecal sample of a Sus scrofa animal, and most closely matches GenBank sequence JX971567.1, which is classified as a P[7] genotype. VP4 amino acids 57-224 (SEQ ID NO: 7) were used, which corresponds to the lectin-like domain of the VP8 protein but has an N-terminal extension of eight amino acid residues. The linker moiety is Gly-Gly-Ser (SEQ ID NO: 11). PCV2 ORF2 (native sequence) encoding an IDT G block, a Gly-Gly-Ser linker, and AVP8 (codon-optimized for insect cells) were received (SEQ ID NO: 22) and are herein designated PCV2-AVP8. The protein encoded by PCV2-AVP8 (SEQ ID NO: 14) is also referred to herein as the "PCV2-AVP8 protein."

[0089] The PCV2-CVP8 sequence uses the same PCV2 ORF2 protein and linker sequences used for PCV2-AVP8, with the CVP8 fusion protein partner sequence encoded by SEQ ID NO: 10. A sequence alignment (PROMALS3D) including secondary structure was used as a design aid, with rotavirus CVP8 VP4 amino acids 57-237 used in the fusion protein. PCV2 ORF2 (native sequence) encoding an IDT Gblock, a Gly-Gly-Ser linker, and CVP8 (codon-optimized for insect cells) are received (SEQ ID NO: 27) and are hereinafter referred to as PCV2-CVP8. The protein encoded by PCV2-CVP8 (SEQ ID NO: 19) is also referred to herein as the "PCV2-CVP8 protein."

[0090] Cloning, expression, purification and electron microscopy: Both PCV2-AVP8 and PCV2-CVP8 were TOPO cloned and subsequently inserted into the baculovirus transfer plasmid pVL1393 using the BamHI and NotI restriction sites, and then co-transfected into Sf9 cells with BaculoGold to generate recombinant baculovirus. Production of PCV2-AVP8 and PCV2-CVP8 proteins was performed as follows: 1 L of Sf+ cells in a 3 L spinner flask was infected at 0.2 MOI with spent medium collected 5 DPI, centrifuged at 15,000 g for 20 minutes, and 0.2 μm filtered. The clarified medium was placed into twelve 1 x 3.5 inch UltraClear centrifuge tubes (Beckman Coulter, catalog no. 344058) at 36 mL per tube and centrifuged at 100,000 g and 4°C for 2 hours. The supernatant was removed, followed by the addition of 300 μL of PBS (Gibco, catalog no. 10010-023) to the pelleted material, followed by incubation at 4°C for 1 hour. The pellet was resuspended and mixed to a final volume of 5 mL (starting from 432 mL, 86.4-fold concentrated). A step gradient of 10-60% sucrose (10% steps) was set up, and 5 mL of concentrate was applied. Centrifuged at 100,000 g and 4°C for 2 hours; a strong band was observed in the bottom third. 2 mL fractions were pipetted from the top, and the fractions were combined based on absorbance at 280 nm. Peak fractions were combined, placed in a 3-12 mL Slide-A-Lyzer (Thermo Scientific, catalog no. 66810), and dialyzed against 3.5 L of TBS with one buffer exchange. The concentrations were determined by BSA assay (Thermo Scientific, catalog number 23227) and were 225.6 μg / mL, approximately 20 mL volume, approximately 4.5 mg yield for PCV2-AVP8 protein, and 90 μg / mL, approximately 27 mL volume, approximately 2.4 mg yield for PCV2-CVP8 protein.

[0091] Samples of PCV2 ORF2 protein, PCV2-AVP8 protein, and PCV2-CVP8 protein were evaluated by negative staining electron microscopy. PCV2 ORF2 VLPs are relatively smooth, icosahedral particles with a diameter of approximately 22 nm, as shown in Figure 1. Electron microscope (EM) images of PCV2-AVP8 protein and PCV2-CVP8 protein revealed VLPs with diameters similar to those of PCV2 VLPs but featuring small nodules on the surface (exemplary illustration for PCV2-CVP8 in Figure 2). These nodules appear to be consistent in size with the rotavirus A and C VP8 protein fragments used.

[0092] Therefore, the electron microscope (i) a fusion protein of SEQ ID NO: 17 comprising a BACV2 capsid protein linked to an immunogenic fragment of a rotavirus A VP8 protein, and (ii) a fusion protein of SEQ ID NO: 18 comprising a BFDV capsid protein linked to an immunogenic fragment of the rotavirus A VP8 protein. It is also possible to visualize VLP formation in baculovirus by ultracentrifugation at 100,000 g to obtain EM images. The baculovirus supernatant was collected and pelleted by ultracentrifugation at 100,000 g. The pellet was resuspended in PBS to obtain a concentration of approximately 50-60 times, which was then run through a 10-60% sucrose gradient at 100,000 g for 2 hours. Samples were pipetted from the top of the gradient and run on SDS-PAGE. Fractions determined to be the peak were combined and dialyzed against TBS, and then EM images were obtained.

[0093] Serological studies: Sucrose gradient-purified PCV2-AVP8 and PCV2-CPV8 proteins were formulated in Emulsigen D, containing 87.5% antigen and 12.5% ​​adjuvant. Pigs approximately 7 weeks old received a 2 mL dose via IM in the flank of the neck with a booster 21 days later. Serum samples were collected weekly for 7 weeks. Serum from pigs vaccinated with PCV2-AVP8 protein was evaluated by ELISA (Figure 3), as described below ("Protocol for ELISA"), and by a virus neutralization assay (Figure 4), as described below ("Protocol for Virus Neutralization Assay"). Compared to the irrelevant vaccine control, IgG ELISA results from pigs vaccinated with PCV2-AVP8 protein showed an increased SP ratio, peaking on day 7 and rising again after the booster on day 21. Virus neutralization titers similarly showed increases on days 7 and 14, followed by a second peak on day 28 after the day 21 boost.

[0094] Protocol for ELISA For the IgA ELISA, 96-well ELISA plates containing media proteins were coated with whole rotavirus antigen diluted 1:16 in 1x PBS. The plates were incubated overnight at 4°C. After incubation, the plates were washed with 1x PBST and then blocked with casein blocking solution at 37°C for 1 hour. After washing, 100 μL of primary antibody diluted to a final dilution of 1:40 in blocking buffer was added to the plates and incubated at 37°C for 1 hour. After washing, the wells were coated with 100 μL of horseradish peroxidase (HRP)-conjugated goat anti-boar IgA diluted 1:3200 and incubated at 37°C for 1 hour. After washing, the plates were developed with 3,5,3',5'-tetramethylbenzidine for 15 minutes at room temperature, and the reaction was stopped with 1N HCl before measuring the optical density (CD) at 450 nm. Samples, including positive and negative controls, are run in duplicate wells and results are reported as the mean ratio (SN) / (PN) of (sample minus negative control) to (positive control minus negative control).

[0095] For IgG ELISA, 96-well ELISA plates containing media proteins were coated with whole rotavirus antigen diluted 1:8 in 1x PBS. The plates were incubated overnight at 4°C. After incubation, the plates were washed with 1x PBST and then blocked with blotting-grade blocking solution at 37°C for 1 hour. After washing, 100 μL of primary antibody diluted to a final dilution of 1:625 in blocking buffer was added to the plates and incubated at 37°C for 1 hour. After washing, the wells were coated with 100 μL of horseradish peroxidase (HRP)-conjugated goat anti-boar IgG diluted 1:8000 and incubated at 37°C for 1 hour. After washing, the plates were developed with 3,5,3',5'-tetramethylbenzidine for 10 minutes at room temperature, the reaction was stopped with 1N HCl, and the optical density (CD) was measured at 450 nm. Samples, including positive and negative controls, are run in duplicate wells and results are reported as the mean ratio (SN) / (PN) of (sample minus negative control) to (positive control minus negative control).

[0096] Protocol for virus neutralization assay All serum and milk samples were heat inactivated at 56°C for 30 minutes. Samples were serially diluted from 1:40 to 1:2,560 in rotavirus growth medium (MEM + 2.5% HEPES + 0.3% tryptose phosphate broth + 0.02% yeast + 10 μg / mL trypsin). Rotavirus A isolates (titer 7.0 log TCID 50Virus (1000 μg / mL) was diluted 1:25,000 in rotavirus growth medium. A total of 200 μl of diluted serum was added to 200 μl of diluted virus, and the mixture was incubated for 1 hour at 37°C ± 5% CO2. Growth medium was aseptically removed from 96-well plates seeded with 3-4 day-old MA104 cells. After incubation, 200 μl of the virus-serum mixture was transferred to cell culture plates. Cells were incubated for 72 hours at 37°C ± 5% CO2. Stock and diluted viruses were titrated on the day of use to confirm the dilutions used in the assay. After incubation, the supernatant was discarded, and the plates were washed once with 200 μL / well of 1x PBS. After fixation, 100 μL / well of 50% / 50% acetone / methanol was added. The plates were incubated at room temperature for 15 minutes, air-dried, and then rehydrated with 100 μL / well of 1×PBS. The primary antibody (rabbit anti-rotavirus A polyclonal serum, generated in-house) was diluted 1:1000 in 1×PBS. 100 μL / well of diluted primary antibody was added, and the plates were incubated for 1 hour at 37°C ± 5% CO2. After incubation, the plates were washed twice with 100 μL / well of 1×PBS. The secondary antibody (Jackson ImmunoResearch FITC-labeled goat anti-rabbit IgG, catalog number 111-095-003) was diluted 1:100 in 1×PBS. 100 μL / well of diluted secondary antibody was added, and the plates were incubated for 1 hour at 37°C ± 5% CO2. After incubation, the plates were washed twice with 100 μL / well of 1×PBS. Plates were read for the presence of fluorescence using an ultraviolet microscope. The assay showed a diluted virus titer (generated using the Reed-Muench method) of 2.8±0.5 log TCID 50 Serum titers were considered valid if they were found to be 0.01 / mL. In addition, known positive and negative samples were included in each assay as controls. Serum titers were reported as the highest dilution at which no staining was observed.

[0097] Example 2 Load study: The primary objective of this study was to evaluate whether conventional administration of a prototype vaccine containing the PCV2-AVP8 protein (SEQ ID NO: 14), also referred to herein as "PCV2:AVP8," and an unrelated control vaccine, also referred to herein as "placebo," to sows conferred passive protection to pigs against a pathogenic rotavirus A challenge. Additionally, for comparison, a commercially available MLV rotavirus vaccine (ProSystem® Rota, Merck Animal Health), also referred to herein as the "commercial product" or "commercial vaccine," was used in the study. The prototype vaccine, PCV2:AVP8, was produced similarly to the production described above in Example 1, but with a different volume used for infection and a longer incubation period, as described in the section "Vaccine Production: PCV2:AVP8" below. The commercial product was used according to the label instructions (dosage and instructions, as well as the recommended method for oral vaccination of Sus scrofa) provided by the manufacturer for the vaccine, ProSystem® TGE / Rota.

[0098] A total of 16 sows were included in the study. The sows were randomized into three treatment groups and one strict control group, as described in Table 1 below. T01 and T02 sows were mixed among three rooms. T06 and T07 sows were housed in two separate rooms. All sows were vaccinated with the appropriate material by the appropriate route, as listed in Table 1. T07 sow remained unvaccinated (strict control). Serum was collected from the sows periodically throughout the vaccination period and assayed for evidence of seroconversion. Fecal samples were collected before farrowing and screened by RT-qPCR to confirm that the dams were not actively shedding rotavirus before farrowing. General health observations were recorded daily for each sow. Farrowing was allowed to occur naturally until the sows reached 114 days of gestation. After this time, farrowing was induced. Piglets were enrolled in the study at the time of farrowing. Only piglets that were healthy at birth were tagged, processed according to the facility's standard operating procedures, and included in the study. When pigs reached 0-5 days of age, they were bled, fecal swabs were collected, and the pigs were challenged (except for T07). At the time of challenge, the pigs were administered a 5 mL dose of sodium bicarbonate intragastrically followed by a 5 mL dose of the challenge material intragastrically. Throughout the challenge period, all animals were monitored daily for the presence of enteric disease (diarrhea and behavioral changes). Fecal samples were collected periodically throughout the challenge period. Two days post-challenge (DPC 2), approximately one-third of the pigs from each litter were euthanized. After euthanasia, necropsies were performed and the pigs were evaluated for gross lesions. Intestinal sections were collected for microscopic and immunohistological evaluation. Intestinal swabs were collected for RT-qPCR evaluation. On DPC 21, all remaining pigs were weighed, bled, and fecal swabs were collected. After sample collection, the pigs were euthanized. The pigs were evaluated for gross lesions and intestinal swabs were collected.

[0099] [Table 1]

[0100] Throughout the study, serum VN titers (shown in Figure 5; virus neutralization was assessed as described above in Example 1 ("Protocol for Virus Neutralization Assay")) of sows from T07 (strict control) remained constant or decreased, indicating lack of exposure and a valid study. During the vaccination phase, the highest median serum VN titers of the four groups were observed in sows vaccinated with the PCV2:AVP8 (T01) prototype vaccine. In this group (T01 (PCV2:AVP8)), one dose administered 6 weeks before farrowing resulted in a greater than four-fold increase in titers in 4 / 5 animals. Sows in the placebo group (T02) did not have a significant increase (<2-fold) in serum VN titers during the vaccination phase. Sows in T06 (commercial vaccine) did not have a significant increase (<2-fold) in serum VN titers until D35. Prior to pig challenge, both sows in T06 (commercial vaccine) had a four-fold increase in titer. After lateral exposure to the challenge material, VN serum titers increased in sows in T02 (placebo) and T06 (commercial vaccine). Conversely, in T01 (PCV2:AVP8), serum VN titers increased in 3 / 5 animals, remained the same in 1 / 5 animals, and decreased in the remaining animals after lateral exposure to the challenge material.

[0101] Regarding colostrum and milk VN titers (data not shown), in group T01 (PCV2:AVP8), VN titers were highest at farrowing, decreased in pre-challenge samples, and further decreased in post-challenge samples. In the placebo group (T02), VN titers were low at farrowing and pre-challenge, but increased after lateral exposure to the challenge material. In group T06 (commercial vaccine), VN titers were highest at farrowing, decreased in pre-challenge samples, and then increased in post-challenge samples. VN titers in pig serum before challenge were high (>1280) in the majority of pigs in T01 (PCV2:AVP8), indicating passive transfer of immunity from sow to pig.

[0102] Throughout the challenge phase, the highest mortality rate among the four groups was observed in T02 (placebo), with 8 / 57 (14.0%) pigs dying. Conversely, only 2 / 45 (4.4%) pigs died in T01 (PCV2:AVP8), 1 / 22 (4.5%) pigs died in T06 (commercial vaccine), and 1 / 27 (3.7%) pigs died in T07 (strict control). Clinical signs of diarrhea were not observed in T07 (strict control) pigs throughout the study. Clinical signs of diarrhea in T02 (placebo) pigs began on day 1 or 2 post-challenge (DPC) and resolved in most animals by DPC10. Overall, clinical signs of diarrhea were observed in 44 / 57 (77.2%) of T02 (placebo) animals at least once during the study. Of these 44 animals, diarrhea was considered severe in 29 (65.9%) animals. In contrast, clinical signs of diarrhea were reduced in T01 (PCV2:AVP8) pigs. See Table 2 below for a summary of clinical diarrhea results by group.

[0103] [Table 2]

[0104] Prior to challenge, no rotavirus A RNA was detected by RT-qPCR, indicating a valid study. Additionally, throughout the study, no rotavirus A RNA was detected by RT-qPCR in sows or pigs from T07 (strict control). In post-challenge pigs, shedding was most prevalent in T02 (placebo). In most pigs, shedding began between DPC 1 and DPC 3 and continued until DPC 14. Most interesting was the reduction in shedding observed in T01 (PCV2:AVP8) compared with T02 (placebo) and T06 (commercial vaccine). Both the percentage of shedding and the median amount of RNA detected were reduced (see Figure 6 for group median log rotavirus A RNA genome copies (gc) / mL in feces by study day; testing was performed as described below ("Protocol for RotaA qRT-PCR")). A randomly selected subset of pigs from each group was euthanized and necropsied on DPC2. Pigs were evaluated for gross intestinal lesions (e.g., thin-walled, gas-distended small intestine, pure liquid content), microscopic lesions (shrunken intestine), and the presence of rotavirus A-specific staining by immunohistochemistry (IHC). Table 3 below shows the number of pigs per group with intestinal lesions at necropsy. The challenge was considered successful because 84.2% (16 / 19) of pigs in the placebo group (T02) had gross lesions, of which 63.2% (12 / 19) were stained. Most interesting was the lack of rotavirus A staining in animals in T01 (PCV2:AVP8). Additionally, there was a reduction in the percentage of pigs with gross lesions in T01 (PCV2:AVP8) compared to T02 (placebo) and the commercial product (T06).

[0105] [Table 3]

[0106] The average daily weight gain (kg) was calculated for the surviving pigs and is shown in Table 4 below. The highest numerical benefit in average daily weight gain (ADWG) of the three vaccinated groups was observed in pigs from T01 (PCV2:AVP8). The increase in ADWG after vaccination was significantly different compared to T02 (placebo).

[0107] [Table 4] In conclusion, vaccination of conventional sows with the PCV2:AVP8 prototype vaccine (comprising the polypeptide of SEQ ID NO: 14) at 6 weeks and 2 weeks before farrowing resulted in high neutralizing antibody titers in the sow's serum and colostrum. These neutralizing antibodies were passively transferred to pigs after birth, as evidenced by the detection of high titers (>1280) in the serum of pigs from vaccinated sows. The presence of high neutralizing antibody titers in pigs confers clinical protection. Specifically, pigs born to vaccinated sows had reduced fecal shedding of rotavirus A RNA, reduced mortality, reduced clinical signs of diarrhea, reduced gross lesions at DPC2, and increased ADWG compared to pigs born to placebo controls and the commercial vaccine.

[0108] Protocol for RotaA qRT-PCR To determine rotavirus A RNA in fecal samples, a quantitative one-step RT-PCR kit (iTaq Universal One-Step RT-PCR Kit; BioRad, catalog number 1725140) was used for the assay. See Table 5 below for primer and probe information.

[0109] [Table 5]

[0110] Real-time RT-PCR was performed in 20 μl reactions containing 5 μl of extracted total nucleic acid, 1 μl of each probe (5 μM), 1 μl of each primer (10 μM), 10 μl of 2× RT-PCR mix, 0.5 μl of iScript reverse transcriptase, and 0.5 μl of DEPC-treated water. Reactions were performed using a CFX96 Real-Time PCR Detection System (BioRad) under the following conditions: initial reverse transcription at 50°C for 10 min, followed by 40 cycles of initial denaturation at 95°C for 3 min, denaturation at 95°C for 15 s, and annealing and extension at 60°C for 45 s. To generate relative quantification data, serial dilutions of two rotavirus A g-blocks were included in each run. Equal amounts of each g-block were used, starting at 5.0 × 10 7 Genome copies / μL were used to include in the run. Optical data were analyzed using CFX Manager software. For each determination, threshold lines were calculated automatically using the regression settings for cycle threshold (Ct) determination mode. Baseline subtraction was performed automatically using the baseline subtraction mode. Curves with a baseline final value of less than 10 were manually corrected.

[0111] Testing for dual immune responses We further tested whether administration of the prototype vaccine PCV2:AVP8 (containing the PCV2-AVP8 protein (SEQ ID NO: 14)) also induced an immune response against PCV2. To this end, the sow sera collected as described above and used for the virus neutralization assay were also tested for the presence of antibodies specific to PCV2. For this purpose, an indirect ELISA (Inmunologia y Genetica Aplicada, SA (INGENASA), INGezim CIRCO IgG kit (R.11.PCV.K1)) was used on the samples according to the manufacturer's instructions. As a result, it was found that animals in T01 clearly had numerically higher anti-PCV2 responses in serum after vaccination with PCV:AVP8 compared to the placebo group, and this was particularly significant in prechallenge samples (Figure 7).

[0112] PCV2:AVP8 generation An 8 L lot of antigen was transferred to 8 L of Sf+ (Spodoptera frugiperda) cells in a 10 L bioreactor at approximately 1 x 10 6 PCV2 ORF2-rotavirus A VP8 core fusion protein (BG / pVL1393-PCV2-AVP8; 4.10 × 10) was cultured at a concentration of 10 cells / mL. 7 TCID 50 Recombinant baculovirus was generated by infecting 14 mL of a recombinant baculovirus stock containing 14 mL of baculovirus (14 mL / mL) with 14 mL of baculovirus stock containing 14 mL of baculovirus (14 mL / mL). The bioreactor was incubated at 28°C ± 2°C with constant agitation of approximately 100 rpm for 9 days. The cells and medium were aseptically transferred to eight 1 L centrifuge bottles, and the cells were pelleted at 10,000 g for 20 minutes at 4°C. The resulting supernatant was passed through a 0.8 / 0.2 μm filter (PolyCap 75TC 0.8 / 0.2 μm filter, 820 cm2 EFA, GE Healthcare, catalog number 6715-7582). The baculovirus was inactivated with 5 mM BEI at 27°C for 5 days and 17 hours, after which it was concentrated 7-fold using a 10,000 NMWC Xampler ultracentrifuge cartridge (GE Healthcare, catalog number UFP-10-C-4MA). The resulting PCV2-AVP8 concentrate (128.9 μg / mL) was diluted to a target concentration of 75 μg / mL in 1×PBS (Gibco Cat. No. 10010-023). The diluted material was formulated with 12.5% ​​Emulsigen D.

[0113] Example 3 Serological studies: The primary objective of this study was to evaluate whether administration of a prototype vaccine containing the PCV2-AVP8 protein (SEQ ID NO: 14) and a control vaccine, referred to herein as "placebo," to conventional sows would result in a serological response to rotavirus A. The prototype vaccine, also referred to herein as "PCV2#AVP8" (containing either Emulsigen D or Carbopol as an adjuvant, see Tables 7 and 7B below), was produced similarly to the production described above in Examples 1 and 2, as described below in the section "Vaccine Production: PCV2'AVP8," but with different volumes used for infection and a longer incubation period.

[0114] A total of 17 sows were included in the study. The sows were randomized into four treatment groups as described in Table 6 below. The sows were intermixed throughout the study. All sows were vaccinated intramuscularly on D0 and D21 with the appropriate material as listed in Table 6. Serum was collected from the sows periodically throughout the study and assayed for evidence of seroconversion by virus neutralization assay. General health observations were recorded daily for each sow. The study was terminated on D42.

[0115] [Table 6]

[0116] Serum VN titers in sows from T06 and T07 (placebo groups) remained constant or decreased throughout the study, indicating non-exposure and validity of the study. (Virus neutralization was assessed as described above in Example 1 ("Protocol for Virus Neutralization Assay").) During the vaccination phase, sows vaccinated with the PCV2#AVP8 / Emulsigen D (T04) and PCV2#AVP8 / Carbopol (T05) prototype vaccines experienced significant increases in titers (>4-fold). For both groups (T04 and T05), group mean titers exceeded 640 after one vaccination and remained above 640 throughout the study. In contrast, sows in the placebo groups (T06 and T07) did not experience significant increases in serum VN titers (<2-fold) throughout the study. In conclusion, vaccination of conventional sows with the PCV2#AVP8 prototype vaccine (comprising the polypeptide of SEQ ID NO: 14) at 6 weeks and 2 weeks before farrowing results in high neutralizing antibody titers in the serum of the sows.

[0117] Vaccine production: PCV2#AVP8 The prototype vaccine PCV2#AVP8 was prepared by incubating 8L of Sf+ cells at 1.00 × 10 6 Cells were grown in 10 L Sartorius Biostat B glass jacketed vessels seeded at a density of 1.21 x 10 cells / mL. Cells were grown using BG / pVL1393-PCV2-AVP8 clone 3E7 / 1F5 (P8, 1.21 x 10 cells / mL). 8 TCID 50The cells were infected with 100 μg / mL of BEI at an MOI of 0.2. The bioreactor was run at 27°C for 10 days with 100 rpm agitation and oxygen diffused at 0.3 standard liters per minute. After incubation, the harvested fluid was centrifuged at 10,000 x g for 20 minutes at 4°C. The supernatant was then passed through a 0.8 / 0.2 μm filter (GE Healthcare, catalog number 6715-3682). The clarified material was inactivated with 5 mM BEI for 5 days and 17 hours at 27°C. After neutralization of the remaining BEI with sodium thiosulfate, the inactivated material was concentrated approximately eight times using a 10 kDa hollow fiber filter (GE, catalog number UFP-10-C-4MA). The concentration was determined to be 13.5 μg / mL. Materials were used to formulate a series containing either Carbopol (Table 7A) or Emulsigen D (Table 7B).

[0118] [Table 7] [Table 8]

[0119] Example 4 Generation of consensus sequences: The consensus sequences of SEQ ID NO:8 (based on the genotype P[6] rotavirus VP8 protein) and SEQ ID NO:9 (based on the genotype P

[13] rotavirus VP8 protein) were generated as described below.

[0120] Sequences were collected from publicly available boar rotavirus VP4 nucleotide sequences from the NCBI Virus Variation database and from internally derived rotavirus isolate sequences. Additional metadata for the sequences was also compiled, including metadata on isolate name, isolate P type, geographic origin, and, when available, date of isolation. Nucleotide sequences were translated into protein sequences and aligned to known VP8 proteins using MUSCLE sequence alignment software with UPGMB clustering and default gap penalty parameters. Non-aligned VP5 amino acids were trimmed and discarded. The aligned VP8 protein sequences were imported into MEGA7 software for phylogenetic analysis, and a neighbor-joining phylogenetic reconstruction was generated based on the VP8 protein sequences. Optimal trees were computed (n = 100) using the Poisson correction method with phylogenetic bootstrap tests and drawn to scale across all 170 positions, with branch lengths equal to the evolutionary distance in units of amino acid substitutions per site. Nodes with bootstrap cluster associations greater than 70% were considered significant. Nodes with a distance of approximately 10% and bootstrap cluster association greater than 70% were designated as clusters. Outlier sequences that did not fit into larger clusters were individually assessed for sequence quality and P-type origin. Suspected low-quality sequences were removed from the analysis, while sequences from P-types rarely observed in boar rotaviruses were retained. Clusters used to generate consensus sequences were selected based on desired product protection profiles and in vitro serum cross-neutralization studies. Consensus sequences were generated by maximal frequency per aligned position, and amino acid residues were selected based on reported epidemiological data in conjunction with product protection profiles, where a comparable proportion of amino acids were observed at aligned positions.

[0121] In the sequence listing / origin and geographic origin (if applicable): SEQ ID NO: 1 corresponds to the sequence of the PCV2 ORF2 protein. SEQ ID NO: 2 corresponds to the sequence of the PCV2 ORF2 protein. SEQ ID NO: 3 corresponds to the sequence of the BACV2 capsid protein. SEQ ID NO: 4 corresponds to the sequence of the BFDV capsid protein. SEQ ID NO: 5 corresponds to the sequence of a rotavirus VP8 protein (genotype P[7]) originating from a farm in North Carolina, USA. SEQ ID NO: 6 corresponds to the sequence of the lectin-like domain of the VP8 protein of a rotavirus (genotype P[7]) originating from a farm in North Carolina, USA. SEQ ID NO: 7 corresponds to the sequence of an immunogenic fragment of the VP8 protein of a rotavirus (genotype P[7]) originating from a farm in North Carolina, USA. SEQ ID NO: 8 corresponds to the sequence of an immunogenic fragment of the rotavirus VP8 protein, ie the consensus sequence of a portion of the rotavirus VP8 protein (based on genotype P[6]). SEQ ID NO: 9 corresponds to the sequence of an immunogenic fragment of the rotavirus VP8 protein, i.e. the consensus sequence of a portion of the consensus sequence of an immunogenic fragment of the rotavirus VP8 protein (based on genotype P

[13] ). SEQ ID NO: 10 corresponds to the sequence of an immunogenic fragment of the rotavirus C VP8 protein.

[0122] SEQ ID NO: 11 corresponds to the sequence of the linker portion. SEQ ID NO: 12 corresponds to the sequence of the linker portion. SEQ ID NO: 13 corresponds to the sequence of the linker portion. SEQ ID NO: 14 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 7. SEQ ID NO: 15 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 8. SEQ ID NO: 16 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 9. SEQ ID NO: 17 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO: 3, SEQ ID NO: 11 and SEQ ID NO: 7. SEQ ID NO: 18 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO: 4, SEQ ID NO: 11 and SEQ ID NO: 7. SEQ ID NO: 19 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 10. SEQ ID NO:20 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO:3, SEQ ID NO:11 and SEQ ID NO:10.

[0123] SEQ ID NO:21 corresponds to the sequence of a polypeptide (fusion protein) comprising the sequences SEQ ID NO:4, SEQ ID NO:11 and SEQ ID NO:10. SEQ ID NO: 22 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO: 14 (fusion protein). SEQ ID NO:23 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO:15 (fusion protein). SEQ ID NO:24 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO:16 (fusion protein). SEQ ID NO: 25 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO: 17 (fusion protein). SEQ ID NO:26 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO:18 (fusion protein). SEQ ID NO: 27 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO: 19 (fusion protein). SEQ ID NO:28 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO:20 (fusion protein). SEQ ID NO:29 corresponds to the sequence of a polynucleotide encoding the polypeptide of SEQ ID NO:21 (fusion protein). SEQ ID NOs: 30 to 33: Primer and probe sequences (Table 3).

[0124] The following clauses are also disclosed herein: Accordingly, the present disclosure further includes aspects featuring the following clauses: 1. A polypeptide comprising a Circoviridae virus capsid protein linked to a heterologous protein or fragment thereof. 2. The polypeptide according to Item 1, wherein the C-terminal amino acid residue of the Circoviridae virus capsid protein is linked to the N-terminal amino acid residue of the heterologous protein or fragment thereof. 3. The Circoviridae virus capsid protein is linked to the heterologous protein or a fragment thereof via a linker moiety; or Item 3. The polypeptide according to Item 1 or 2, wherein the Circoviridae virus capsid protein is linked to the heterologous protein or a fragment thereof via a peptide bond between the C-terminal amino acid residue of the Circoviridae virus capsid protein and the N-terminal amino acid residue of the heterologous protein or a fragment thereof. 4. The polypeptide according to any one of Items 1 to 3, wherein the polypeptide is a fusion protein.

[0125] 5. The polypeptide has the formula xyz, wherein: x consists of or comprises a Circoviridae virus capsid protein; y is a linker moiety, z is a heterologous protein or a fragment thereof A polypeptide that is a fusion protein of any one of Items 1 to 4, particularly a polypeptide according to any one of Items 1 to 4. 6. The polypeptide according to any one of Items 1 to 5, wherein the heterologous protein or fragment thereof consists of an amino acid sequence that is at least 50 amino acid residues in length, preferably at least 100 amino acid residues in length, and most preferably at least 150 amino acid residues in length. 7. The polypeptide according to any one of Items 1 to 6, wherein the heterologous protein or a fragment thereof comprises or consists of an amino acid sequence having a length of 50 to 1,000 amino acid residues, preferably 100 to 500 amino acid residues, and most preferably 150 to 250 amino acid residues. 8. The polypeptide according to any one of items 1 to 7, wherein the heterologous protein or fragment thereof comprises or consists of a protein domain, and the protein domain is preferably at least 50 amino acid residues in length, more preferably at least 100 amino acid residues in length, and most preferably at least 150 amino acid residues in length.

[0126] 9. The peptide according to any one of Items 1 to 8, wherein the heterologous protein or fragment thereof is a non-Circoviridae protein or fragment thereof, and / or the heterologous protein or fragment thereof is a protein or fragment thereof encoded by the genome of a pathogen other than a Circoviridae virus.

[0127] 10. The polypeptide according to any one of Items 1 to 9, wherein the heterologous protein or a fragment thereof is a protein or a fragment thereof encoded by the genome of a virus other than a Circoviridae virus. 11. The polypeptide according to any one of Items 1 to 10, wherein the Circoviridae virus is selected from the group consisting of Porcine Circovirus Type 2 (PCV2), Bat-Associated Circovirus 2 (BACV2), and Beak and Feather Disease Virus (BFDV). 12. The polypeptide according to any one of Items 1 to 11, wherein the Circoviridae virus is PCV2, and the PCV2 is preferably selected from the group consisting of PCV2 subtype a (PCV2a) and PCV2 subtype d (PCV2d). 13. The polypeptide according to any one of Items 1 to 12, wherein the Circoviridae virus capsid protein is selected from the group consisting of PCV2 ORF2 protein, BACV2 capsid protein, and BFDV capsid protein. 14. The polypeptide according to any one of Items 1 to 13, wherein the Circoviridae virus capsid protein is a PCV2 ORF2 protein, and the PCV2 ORF2 protein is preferably selected from the group consisting of a PCV2 subtype a (PCV2a) ORF2 protein and a PCV2 subtype d (PCV2d) ORF2 protein.

[0128] 15. The polypeptide of any one of items 1 to 14, wherein the Circoviridae viral capsid protein comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4. 16. The polypeptide according to any one of items 1 to 15, wherein the heterologous protein or a fragment thereof is a rotavirus protein or a fragment thereof. 17. The polypeptide according to any one of Items 1 to 16, wherein the heterologous protein or a fragment thereof is a rotavirus VP8 protein or a fragment thereof. 18. The polypeptide of any one of paragraphs 1 to 17, wherein the heterologous protein or fragment thereof comprises or is an immunogenic fragment of a rotavirus VP8 protein. 19. The polypeptide according to any one of items 1 to 18, wherein the heterologous protein or fragment thereof is an immunogenic fragment of a rotavirus VP8 protein. 20. The polypeptide of paragraph 18 or 19, wherein the immunogenic fragment of the rotavirus VP8 protein is capable of inducing an immune response against rotavirus in a subject to which the immunogenic fragment of the rotavirus VP8 protein is administered. 21. The polypeptide according to any one of items 18 to 20, wherein the immunogenic fragment of the rotavirus VP8 protein is 50 to 200, preferably 140 to 190, amino acid residues in length.

[0129] 22. The polypeptide according to any one of Items 16 to 21, wherein the rotavirus is a porcine rotavirus. 23. The polypeptide according to any one of Items 16 to 22, wherein the rotavirus is selected from the group consisting of rotavirus A and rotavirus C. 24. The polypeptide according to any one of Items 16 to 23, wherein the rotavirus is rotavirus A. 25. The polypeptide of any one of items 16 to 24, wherein the immunogenic fragment of rotavirus VP8 protein comprises a lectin-like domain of rotavirus VP8 protein. 26. The polypeptide of any one of items 16 to 25, wherein the immunogenic fragment of rotavirus VP8 protein is an N-terminally extended lectin-like domain of rotavirus VP8 protein, and the N-terminal extension is 1 to 20 amino acid residues, preferably 5 to 15 amino acid residues, in length.

[0130] 27. The polypeptide according to item 25 or 26, wherein the lectin-like domain of rotavirus VP8 protein consists of the amino acid sequence of amino acid residues 65 to 224 of rotavirus VP8 protein. 28. The polypeptide according to item 26 or 27, wherein the amino acid sequence of the N-terminal extension is an amino acid sequence of a particular length adjacent to the N-terminal amino acid residue of the lectin-like domain in the amino acid sequence of the rotavirus VP8 protein. 29. The polypeptide according to any one of Items 16 to 28, wherein the immunogenic fragment of rotavirus VP8 protein consists of the amino acid sequence of amino acid residues 60 to 224, amino acid residues 59 to 224, amino acid residues 58 to 224, amino acid residues 57 to 224, amino acid residues 56 to 224, amino acid residues 55 to 224, amino acid residues 54 to 224, amino acid residues 53 to 224, amino acid residues 52 to 224, amino acid residues 51 to 224, amino acid residues 50 to 224, or amino acid residues 49 to 224 of rotavirus VP8 protein. 30. The polypeptide according to any one of Items 16 to 29, wherein the immunogenic fragment of the rotavirus VP8 protein consists of the amino acid sequence of amino acid residues 57 to 224 of the rotavirus VP8 protein.

[0131] 31. The polypeptide of any one of items 27 to 30, wherein the numbering of the amino acid residues refers to the amino acid sequence of a wild-type rotavirus VP8 protein, particularly a wild-type rotavirus A VP8 protein, and the wild-type rotavirus VP8 protein is preferably the protein set forth in SEQ ID NO: 5. 32. The polypeptide according to any one of items 16 to 31, wherein the rotavirus is selected from the group consisting of genotype P[7] rotavirus, genotype P[6] rotavirus, and genotype P

[13] rotavirus. 33. The polypeptide of any one of clauses 16 to 32, wherein the rotavirus VP8 protein comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to the sequence of SEQ ID NO: 5.

[0132] 34. The polypeptide according to any one of items 25 to 33, wherein the lectin-like domain of the rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with the sequence of SEQ ID NO: 6. 35. The polypeptide of any one of clauses 16 to 34, wherein the immunogenic fragment of the rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to the sequence of SEQ ID NO: 7. 36. The immunogenic fragment of a rotavirus VP8 protein consists of or is a consensus sequence of a portion of a rotavirus VP8 protein, in particular a portion of a rotavirus A VP8 protein; The consensus sequence of a portion of the rotavirus VP8 protein is preferably - translating the plurality of nucleotide sequences encoding portions of the rotavirus VP8 protein into amino acid sequences; - aligning said amino acid sequence with known rotavirus VP8 proteins, preferably by using the MUSCLE sequence alignment software UPGMB clustering and default gap penalty parameters; - subjecting the aligned sequences to phylogenetic analysis and generating a neighbor-joining phylogenetic reconstruction based on rotavirus VP8 protein sequences, in particular importing the aligned amino acid sequences into MEGA7 software for phylogenetic analysis and generating a neighbor-joining phylogenetic reconstruction based on rotavirus VP8 protein sequences, - calculating the optimal tree using the Poisson correction method with phylogenetic bootstrap tests (n=100); - drawing a scaled optimal tree across all 170 positions in units of amino acid substitutions per site with branch lengths equal to the evolutionary distance; - considering as significant nodes those with bootstrap cluster associations higher than 70%; - designating as clusters nodes that have a distance of approximately 10% and a bootstrap cluster association of greater than 70%; and - generating a consensus sequence by selecting clusters and identifying the maximum frequency per aligned position within the clusters; and - optionally selecting amino acid residues based on reported epidemiological data in conjunction with predefined product protection profiles when an equivalent proportion of amino acids is observed at the aligned positions. Item 36. The polypeptide according to any one of Items 16 to 35, which can be obtained by a method comprising:

[0133] 37. The polypeptide of any one of paragraphs 16 to 36, wherein the immunogenic fragment of rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 9. 38. The polypeptide of any one of items 16 to 23, wherein the rotavirus is rotavirus C. 39. The polypeptide of any one of paragraphs 16 to 23 and 38, wherein the immunogenic fragment of rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to the sequence of SEQ ID NO: 10.

[0134] 40. The heterologous protein or fragment thereof is - an immunogenic fragment of the rotavirus A VP8 protein as defined in any one or more of paragraphs 24 to 35, or - a consensus sequence of a part of a rotavirus VP8 protein, in particular a part of a rotavirus A VP8 protein, as defined in paragraph 36 or 37, or - an immunogenic fragment of the rotavirus C VP8 protein as defined in paragraph 38 or 39, Item 40. The polypeptide according to any one of Items 1 to 39, which consists of, or is an immunogenic fragment or consensus sequence as described above. 41. The polypeptide of any one of items 1 to 40, wherein the heterologous protein or fragment thereof comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

[0135] 42. The polypeptide according to any one of Items 3 to 41, wherein the linker portion is an amino acid sequence having a length of 1 to 50 amino acid residues. 43. The polypeptide according to any one of items 3 to 42, wherein the linker moiety comprises or consists of an amino acid sequence having at least 66%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or particularly 100% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. 44. The polypeptide according to any one of items 1 to 43, which is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or particularly 100% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.

[0136] 45. The polypeptide of any one of items 1 to 44, which is a recombinant protein, preferably a recombinant baculovirus-expressed protein. 46. ​​The polypeptide of any one of items 1 to 45, which can assemble with a plurality of identical polypeptides to form a virus-like particle. 47. The polypeptide of paragraph 46, wherein the heterologous protein or fragment thereof is displayed on the outer surface of the virus-like particle. 48. A virus-like particle comprising or consisting of a plurality of polypeptides according to any one of items 1 to 47. 49. The virus-like particle of clause 48, wherein the heterologous protein or fragment thereof is displayed on the outer surface of the virus-like particle.

[0137] 50. An immunogenic composition comprising the polypeptide according to any one of items 1 to 47 and / or the virus-like particle according to item 48 or 49. 51. The immunogenic composition of paragraph 50, further comprising a pharmaceutically or veterinarily acceptable carrier or excipient. 52. The immunogenic composition of paragraph 50 or 51, further comprising an adjuvant. 53. A polypeptide according to any one of items 1 to 47 and / or a virus-like particle according to item 48 or 49, and a pharmaceutically or veterinarily acceptable carrier or excipient, and optionally, an adjuvant, An immunogenic composition comprising or consisting of: 54. The immunogenic composition of paragraph 52 or 53, wherein the adjuvant is an emulsified oil-in-water adjuvant. 55. The immunogenic composition of paragraph 52 or 53, wherein the adjuvant is carbomer.

[0138] 56. A polynucleotide comprising a nucleotide sequence encoding the polypeptide according to any one of items 1 to 47. 57. The polynucleotide of paragraph 56, comprising a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or especially 100% sequence identity to a sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29. 58. A plasmid, preferably an expression vector, comprising a polynucleotide comprising a sequence encoding the polypeptide according to any one of items 1 to 47. 59. A cell comprising a plasmid, preferably an expression vector, containing a polynucleotide comprising a sequence encoding the polypeptide according to any one of items 1 to 47.

[0139] 60. A baculovirus containing a polynucleotide comprising a sequence encoding the polypeptide according to any one of items 1 to 47. 61. A cell, preferably an insect cell, containing a baculovirus containing a polynucleotide comprising a sequence encoding the polypeptide of any one of items 1 to 47. 62. For the preparation of medicines, preferably vaccines, - the polypeptide according to any one of items 1 to 47, - a virus-like particle according to item 48 or 49, - the immunogenic composition according to any one of items 50 to 55; - a polynucleotide according to item 56 or 57, - a plasmid according to paragraph 58, - the cell according to paragraph 59 or 61, and / or - a baculovirus according to paragraph 60, Use of.

[0140] 63. The polypeptide of any one of paragraphs 1 to 47 or the immunogenic composition of any one of paragraphs 50 to 55 for use as a pharmaceutical. 64. The polypeptide of any one of paragraphs 1 to 47 or the immunogenic composition of any one of paragraphs 50 to 55 for use as a vaccine. 65. The polypeptide of any one of clauses 1 to 47 or the immunogenic composition of any one of clauses 50 to 55 for use in a method for reducing or preventing one or more clinical signs or disease caused by infection by a pathogen. 66. The polypeptide or immunogenic composition of paragraph 65, wherein the pathogen is of a species having a genome encoding the heterologous protein or fragment thereof. 67. The polypeptide of any one of clauses 1 to 47 or the immunogenic composition of any one of clauses 50 to 55 for use in a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in a subject, or for use in a method of treating or preventing rotavirus infection in a subject.

[0141] 68. The polypeptide of any one of clauses 1 to 47 or the immunogenic composition of any one of clauses 50 to 55 for use in a method for inducing an immune response against rotavirus in a subject. 69. In the subject, A method for inducing an immune response against a pathogen of a species having a genome encoding a heterologous protein or fragment thereof; and A method for inducing an immune response against a Circoviridae virus, wherein the Circoviridae virus is preferably of a species that encodes said Circoviridae capsid protein; A polypeptide according to any one of Items 1 to 47 or an immunogenic composition according to any one of Items 50 to 55 for use in

[0142] 70. The polypeptide of any one of paragraphs 1 to 47 or the immunogenic composition of any one of paragraphs 50 to 55 for use in a method for inducing an immune response against rotavirus and PCV2 in a subject. 71. The polypeptide or immunogenic composition of any one of paragraphs 67 to 70, wherein the subject is a mammal or a bird, and the bird is preferably a chicken. 72. The polypeptide or immunogenic composition of any one of paragraphs 67 to 71, wherein the subject is a mammal, and the mammal is preferably a Suidae or Bovidae. 73. The polypeptide or immunogenic composition of any one of paragraphs 67 to 72, wherein the subject is a pig, and the pig is preferably a piglet or sow. 74. The polypeptide or immunogenic composition of paragraph 67, wherein the subject is a piglet.

[0143] 75. The polypeptide or immunogenic composition of any one of paragraphs 68 to 70, wherein the subject is a pregnant sow. 76. The polypeptide of any one of clauses 1 to 47 or the immunogenic composition of any one of clauses 50 to 55 for use in a method of reducing or preventing one or more clinical signs, mortality or faecal shedding caused by rotavirus infection in piglets, wherein the piglets are suckled by a sow to which the immunogenic composition has been administered. 77. The polypeptide or immunogenic composition of paragraph 76, wherein the sow to which the immunogenic composition has been administered is a sow to which the immunogenic composition has been administered while the sow is pregnant, in particular while the sow is pregnant with the piglet.

[0144] 78.- One or more clinical signs caused by infection with a pathogen of a species whose genome encodes a heterologous protein or a fragment thereof; and - one or more clinical signs caused by infection with a Circoviridae virus, wherein the Circoviridae virus is preferably a virus of a species encoding said Circoviridae capsid protein, A polypeptide according to any one of Items 1 to 47 or an immunogenic composition according to any one of Items 50 to 55 for use in a method for reducing or preventing an infection. 79. One or more clinical signs, mortality or fecal shedding caused by rotavirus infection; and - One or more clinical signs, mortality, or nasal discharge caused by PCV2 A polypeptide according to any one of Items 1 to 47 or an immunogenic composition according to any one of Items 50 to 55 for use in a method for reducing or preventing an infection.

[0145] 80. A method for treating or preventing rotavirus infection, reducing, preventing or treating one or more clinical signs, mortality or fecal shedding caused by rotavirus infection, or preventing or treating a disease caused by rotavirus infection, the method comprising the step of administering to a subject a polypeptide described in any one of paragraphs 1 to 47 or an immunogenic composition described in any one of paragraphs 50 to 55. 81. A method for inducing the production of rotavirus-specific antibodies in a sow, the method comprising the step of administering to the sow a polypeptide described in any one of paragraphs 1 to 47 or an immunogenic composition described in any one of paragraphs 50 to 55. 82. A method for reducing or preventing one or more clinical signs, mortality, or fecal shedding caused by infection with rotavirus in piglets, comprising: - administering to a sow a polypeptide according to any one of paragraphs 1 to 47 or an immunogenic composition according to any one of paragraphs 50 to 55; and - the piglet is suckled by the sow. The method comprising: 83. The method of paragraph 82, wherein the sow is pregnant, in particular a sow that is pregnant with the piglet.

[0146] 84. - Administering a polypeptide according to any one of paragraphs 1 to 47 or an immunogenic composition according to any one of paragraphs 50 to 55 to a sow pregnant with said piglets, - allowing the sow to give birth to the piglets; and - the piglet is suckled by the sow. Item 84. The method of item 82 or 83, comprising: 85. A method for reducing or preventing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in piglets, wherein the piglets are suckled by a sow to which a polypeptide according to any one of paragraphs 1 to 47 or an immunogenic composition according to any one of paragraphs 50 to 55 has been administered.

[0147] 86. The one or more clinical signs are: - diarrhea, - pathogen colonization, in particular colonization of a pathogen of a species having a genome encoding a heterologous protein or a fragment thereof, said pathogen colonization being preferably rotavirus colonization, - Lesions, especially gross lesions, - A reduction in average daily weight gain, and - Gastroenteritis The polypeptide or immunogenic composition according to any one of Items 65 to 79 or the method according to any one of Items 80 to 85, wherein the polypeptide or immunogenic composition is selected from the group consisting of: 87. The polypeptide or immunogenic composition of clause 86 or the method of clause 86, wherein the pathogen colonisation is intestinal rotavirus colonisation and / or the lesion is an intestinal lesion.

[0148] 88.- The rotavirus infection is an infection with genotype P

[23] rotavirus and / or genotype P[7] rotavirus; - the rotavirus infection is an infection with genotype P

[23] rotavirus and / or genotype P[7] rotavirus, - the immune response against rotavirus is an immune response against genotype P

[23] rotavirus and / or genotype P[7] rotavirus, or - the rotavirus-specific antibody is an antibody specific to genotype P

[23] rotavirus and / or genotype P[7] rotavirus, The polypeptide or immunogenic composition according to any one of Items 65 to 79, 86 and 87, or the method according to any one of Items 80 to 87. 89. The polypeptide according to item 88, characterized in that the polypeptide is a polypeptide according to any one of items 1 to 37 and 40 to 47, and the fragment of the heterologous protein is an immunogenic fragment of genotype P[7] rotavirus VP8 protein.

[0149] 90. The immunogenic composition according to item 88, comprising a polypeptide according to any one of items 1 to 37 and 40 to 47, wherein the fragment of the heterologous protein is an immunogenic fragment of the VP8 protein of genotype P[7] rotavirus. 91. - A polypeptide according to any one of paragraphs 1 to 37 and 40 to 47, characterized in that the fragment of the heterologous protein is an immunogenic fragment of the VP8 protein of genotype P[7] rotavirus, or - An immunogenic composition comprising the polypeptide according to any one of items 1 to 37 and 40 to 47, characterized in that the fragment of the heterologous protein is an immunogenic fragment of the VP8 protein of genotype P[7] rotavirus. 89. The method of claim 88, wherein said compound is administered or has been administered.

[0150] 92.- The fragment consists of an amino acid sequence that has at least 90%, preferably at least 95%, more preferably at least 98%, or even more preferably at least 99% sequence identity with the sequence of SEQ ID NO: 7, and / or - the polypeptide is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 14, The polypeptide of paragraph 89, the immunogenic composition of paragraph 90, or the method of paragraph 91.

[0151] 93. A method for producing a polypeptide according to any one of paragraphs 1 to 47 and / or a virus-like particle according to paragraph 48 or 49, the method comprising transfecting a cell with a plasmid according to paragraph 58. 94. A method for producing a polypeptide according to any one of paragraphs 1 to 47 and / or a virus-like particle according to paragraph 48 or 49, the method comprising the step of infecting a cell, preferably an insect cell, with a baculovirus according to paragraph 60.

Claims

1. A fusion protein comprising a Circoviridae virus capsid protein linked to a fragment of a heterologous protein, said fragment consisting of an amino acid sequence at least 50 amino acid residues in length, said fragment being an immunogenic fragment of a rotavirus VP8 protein, said fragment consisting of an amino acid sequence having at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:

10.

2. Formula xyz (wherein, x consists of or comprises a Circoviridae virus capsid protein; y is a linker moiety; z is a fragment of a heterologous protein and The fragment is an immunogenic fragment of a rotavirus VP8 protein, and the fragment consists of an amino acid sequence having at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO:

10. The fusion protein.

3. the Circoviridae viral capsid protein is selected from the group consisting of Porcine Circovirus Type 2 (PCV2) ORF2 protein, Bat-Associated Circovirus 2 (BACV2) capsid protein, and Beak and Feather Disease Virus (BFDV) capsid protein; and / or The Circoviridae virus capsid protein comprises or consists of an amino acid sequence having at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4; The fusion protein according to claim 1 or 2.

4. The fusion protein according to any one of claims 1 to 3, wherein the rotavirus is a porcine rotavirus and / or the rotavirus is selected from the group consisting of rotavirus A and rotavirus C.

5. The fusion protein according to any one of claims 1 to 4, wherein the immunogenic fragment of rotavirus VP8 protein is an N-terminally extended lectin-like domain of rotavirus VP8 protein, the lectin-like domain of rotavirus VP8 protein consisting of amino acid residues 65 to 224 of rotavirus VP8 protein, and the N-terminal extension is 1 to 20 amino acid residues in length.

6. The fusion protein according to any one of claims 1 to 5, wherein the rotavirus is selected from the group consisting of genotype P[7] rotavirus, genotype P[6] rotavirus, and genotype P[13] rotavirus.

7. The immunogenic fragment of the rotavirus VP8 protein consists of or is a consensus sequence of a portion of the rotavirus VP8 protein. The fusion protein according to any one of claims 1 to 6.

8. the linker moiety is an amino acid sequence that is 1 to 50 amino acid residues in length; and / or The linker portion comprises or consists of an amino acid sequence having at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO:

13. The fusion protein according to any one of claims 2 to 7.

9. The fusion protein according to any one of claims 1 to 8, which is a protein comprising or consisting of an amino acid sequence having at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:

21.

10. A virus-like particle comprising or consisting of a plurality of fusion proteins according to any one of claims 1 to 9.

11. An immunogenic composition comprising the fusion protein of any one of claims 1 to 9 and / or the virus-like particle of claim 10.

12. A polynucleotide comprising a nucleotide sequence encoding the fusion protein of any one of claims 1 to 9.

13. A medicament comprising the fusion protein according to any one of claims 1 to 9 or the immunogenic composition according to claim 11.

14. 14. The pharmaceutical composition of claim 13 for reducing or preventing one or more clinical signs, mortality or fecal shedding caused by rotavirus infection in a subject, or for treating or preventing rotavirus infection in a subject, and / or for inducing an immune response against rotavirus in a subject.

15. In the subject, To induce an immune response against rotavirus, and The pharmaceutical composition according to claim 13, for inducing an immune response against a Circoviridae virus.

16. 1. A method for reducing or preventing one or more clinical signs, mortality or fecal shedding caused by infection with rotavirus in piglets, comprising: - administering to sows a fusion protein according to any one of claims 1 to 9 or an immunogenic composition according to claim 11, and - the piglets are suckled by the sow. The method comprising:

17. One or more clinical signs: - diarrhea, - rotavirus colonization, - Lesions, - a reduction in average daily weight gain, and - Gastroenteritis The pharmaceutical composition of claim 14, selected from the group consisting of:

18. One or more clinical signs: - diarrhea, - rotavirus colonization, - Lesions, - a reduction in average daily weight gain, and - Gastroenteritis 17. The method of claim 16, selected from the group consisting of:

19. - the rotavirus infection is an infection with genotype P[23] rotavirus and / or genotype P[7] rotavirus, - the rotavirus infection is an infection with genotype P[23] rotavirus and / or genotype P[7] rotavirus, or the immune response against rotavirus is an immune response against genotype P[23] rotavirus and / or genotype P[7] rotavirus, 18. The pharmaceutical composition according to any one of claims 14, 15 or 17.

20. - the rotavirus infection is an infection with genotype P[23] rotavirus and / or genotype P[7] rotavirus, - the rotavirus infection is an infection with genotype P[23] rotavirus and / or genotype P[7] rotavirus, or the immune response against rotavirus is an immune response against genotype P[23] rotavirus and / or genotype P[7] rotavirus, 19. The method of claim 16 or 18.

21. - transfecting a cell with a plasmid comprising a polynucleotide according to claim 12, or - infecting insect cells with a baculovirus containing the polynucleotide of claim 12; 11. A method for producing a fusion protein according to any one of claims 1 to 9 and / or a virus-like particle according to claim 10, comprising:

Images